

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 2855513 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 07 K 14/175 (2006.01)** **A 61 K 39/12 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2017-03-13**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2016-12-07**
- (86) Europæisk ansøgning nr.: **13728288.5**
- (86) Europæisk indleveringsdag: **2013-05-29**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-04-08**
- (86) International ansøgning nr.: **US2013043146**
- (87) Internationalt publikationsnr.: **WO2013181270**
- (30) Prioritet: **2012-06-01 EP 12170631** **2013-03-05 EP 13157875**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Boehringer Ingelheim Vetmedica GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Tyskland**
- (72) Opfinder: **NIKOLIN, Veljko, c/o Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein, Tyskland**
STADLER, Konrad, c/o Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein, Tyskland
LISCHEWSKI, Axel, c/o Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein, Tyskland
BRIX, Alexander, c/oVP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368, USA
KNITTEL, Jeffrey P., c/oVP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O.Box 368, Ridgefield, CT 06877-0368, USA
TOEPFER, Katharina Hedwig, c/o Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein, Tyskland
- (74) Fuldmægtig i Danmark: **Awapatent A/S, Strandgade 56, 1401 København K, Danmark**
- (54) Benævnelse: **SCHMALLENBERGVIRUS-(SBV)-VACCINE, FREMGANGSMÅDER TIL FREMSTILLING OG BRUG DERAFT**
- (56) Fremdragne publikationer:
BERND HOFFMANN ET AL.: "Novel Orthobunyavirus in Cattle, Europe, 2011", EMERGING INFECTIOUS DISEASES, vol. 18, no. 3, 1 March 2012 (2012-03-01), pages 469-472, XP055054135, ISSN: 1080-6040, DOI: 10.3201/eid1803.111905 cited in the application & DATABASE EMBL [Online] 16 January 2012 (2012-01-16), "Schmallenberg virus genes for nucleocapsid protein and non-structural protein, segment S, genomic RNA, isolate BH80/11-4", retrieved from EBI accession no. EM_STD:HE649914 Database accession no. HE649914
IKEGAMI T ET AL.: "Rift Valley fever vaccines", VACCINE, ELSEVIER LTD, GB, vol. 27, 5 November 2009 (2009-11-05), pages D69-D72, XP026694008, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2009.07.046 [retrieved on

Fortsættes ...

2009-10-28]

MUTIEN-MARIE GARIGLIANY ET AL: "Schmallenberg virus: A new Shamonda/Sathuperi-like virus on the rise in Europe", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 95, no. 2, 25 May 2012 (2012-05-25), pages 82-87, XP028426110, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2012.05.014 [retrieved on 2012-06-05]

TOHRU YANASE ET AL: "Genetic reassortment between Sathuperi and Shamonda viruses of the genus in nature: implications for their genetic relationship to Schmallenberg virus", ARCHIVES OF VIROLOGY ; OFFICIAL JOURNAL OF THE VIROLOGY DIVISION OF THE INTERNATIONAL UNION OF MICROBIOLOGICAL SOCIETIES, SPRINGER-VERLAG, VI, vol. 157, no. 8, 16 May 2012 (2012-05-16), pages 1611-1616, XP035091855, ISSN: 1432-8798, DOI: 10.1007/S00705-012-1341-8

KERSTIN WERNIKE ET AL: "Inactivated Schmallenberg virus prototype vaccines", VACCINE, 1 May 2013 (2013-05-01), XP55070055, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2013.05.062

KERSTIN WERNIKE ET AL: "Schmallenberg virus challenge models in cattle: infectious serum or culture-grown virus?", VETERINARY RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, vol. 43, no. 1, 11 December 2012 (2012-12-11), page 84, XP021134454, ISSN: 1297-9716, DOI: 10.1186/1297-9716-43-84

ELLIOTT RICHARD M ET AL: "Establishment of a reverse genetics system for Schmallenberg virus, a newly emerged orthobunyavirus in Europe.", THE JOURNAL OF GENERAL VIROLOGY APR 2013, vol. 94, no. Pt 4, April 2013 (2013-04), pages 851-859, XP002700255, ISSN: 1465-2099

DESCRIPTION

BACKGROUND OF THE INVENTION

TECHNICAL FIELD

[0001] The present invention belongs to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases. In particular, it relates to inactivated viruses useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by Schmallenberg virus.

BACKGROUND INFORMATION

[0002] A novel orthobunyavirus, the Schmallenberg virus (SBV), was discovered in Europe in November 2011. After the first detection, the reported cases of SBV in sheep, cattle, and goats dramatically accumulated in several European countries to several thousand cases of PCR-positive malformed lambs and calves (1, 2). The virus was detected by metagenomics at the Friedrich-Loeffler-Institut (FLI) in samples of cattle with milk drop and fever. The investigated samples were collected in a farm near the city of Schmallenberg (North Rhine-Westphalia, Germany), and consequently the virus was named Schmallenberg virus (SBV). SBV is a member of the genus *Orthobunyavirus* within the family *Bunyaviridae*. It is related to the so-called Simbu serogroup viruses (1).

[0003] Orthobunyaviruses have a segmented, negative stranded RNA genome and are mainly transmitted by insect vectors like midges and mosquitos. The three segments (S, M and L) of the Orthobunyavirus genome allow genetic reassortment, which naturally occurs resulting in the emergence of viruses with new biological properties (3). The largest segment L encodes the RNA-dependent RNA polymerase. The M-segments encodes the viral surface glycoproteins Gn and Gc which are responsible for cell fusion, viral attachment and the induction of neutralizing antibodies. The small S-segment encodes the nucleocapsid N which is also involved in complement fixation (4). The relationship between Orthobunyaviruses was often only determined by serological cross-reactivity (5). In the era of DNA sequencing, phylogenetics has additionally been assessed by comparison of partial genome sequences (full N and partial Gc gene) (6). Therefore, available and published genome sequence information of full-length genomes is sparse. As a consequence, in-depth phylogenetic analyses are difficult. In conclusion, a detailed and reliable taxonomic classification of SBV could not be made. Preliminary investigations showed similarities of the M- and L-segment sequences to partial AKAV and Aino virus (AINOV) sequences. The N gene was most closely related to Shamonda virus (SHAV) (1).

[0004] SBV is like Akabane virus (AKAV) able to cross the placental barrier in pregnant cows and sheep, infect the fetus and cause fatal congenital defects during a susceptible stage in pregnancy (2). The Simbu serogroup, named after the prototype virus, is the largest serogroup of Orthobunyavirus and contains at least 25 viruses, among them medically important viruses such as Akabane virus, Oropouche virus, Sathuperi virus or Douglas virus, most of which can cause malformations in new born ruminants, but also human beings can be affected. Akabane virus, for instance, causes congenital defects in ruminants and circulates in Asia, Oceania and Africa, whereas Oropouche virus is responsible for large epidemics of Oropouche fever, a zoonosis similar to dengue fever, in human populations in South America. Sathuperi virus has lent his name to the Sathuperi serogroup, to which belong also Douglas virus and SBV.

[0005] SBV was the first orthobunyavirus of the Simbu serogroup detected in Europe. The virus is apparently transmitted by arthropod vectors. Biting midges probably play an important role in transmission. According to the current state of knowledge, ruminants are susceptible to infection with SBV. Adult animals may develop mild disease, if any. However, transplacental infection occurs frequently and can lead to severe congenital malformation of the vertebral column (Kyphosis, lordosis, scoliosis, torticollis) and of the skull (macrocephaly, brachygnathia inferior) as well as variable malformations of the brain (hydracephaly, porencephaly, cerebellar hypoplasia, hapoplasia of the brain stem) and of the spinal cord in lambs, kids and calves. The infection spread rapidly over large parts of North Western Europe. Belgium, Germany, France, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom have been affected so far.

[0006] Therefore, SBV is a serious threat to ruminant livestock in Europe since vaccines are currently not available.

[0007] Thus, there is a strong need for vaccines and medications effecting a rapid induction of neutralizing antibodies for the prophylaxis and treatment of Schmallenberg virus infection.

DESCRIPTION OF THE INVENTION

[0008] The solution to the above technical problem is achieved by the description and the embodiments characterized in the claims.

[0009] Thus, the invention in its different aspects is implemented according to the claims.

[0010] In one aspect, the disclosure provides an immunogenic composition containing one or more antigens of the Schmallenberg virus (SBV), wherein the immunogenic composition preferably comprises the SBV.

[0011] Preferably, SBV is thus contained as the one or more antigens of SBV in the composition of the disclosure, or the one or more antigens of the SBV is/are preferably SBV, respectively. Hence, the immunogenic composition of the disclosure is in particular an immunogenic composition comprising Schmallenberg virus (SBV).

[0012] As used herein, the term "antigen" in particular refers to any molecule, moiety or entity capable of eliciting an immune response. This includes cellular and/or humoral immune responses. Depending on the intended function of the composition, one or more antigens may be included.

[0013] The antigen of SBV or the SBV contained in the immunogenic composition of the invention is inactivated.

[0014] According to one aspect, the immunogenic composition of the invention is thus an immunogenic composition comprising inactivated Schmallenberg virus (SBV).

[0015] The term "inactivated", as used herein, means that the antigen does not cause disease, when administered to a mammalian host or does not replicate in a host cell.

[0016] The invention also provides an immunogenic composition comprising SBV or an antigen of SBV, wherein the SBV comprises

- a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 %, preferably at least 99 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7,
- a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2, and/or
- a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3.

[0017] Preferably, said SBV comprises said small (S) RNA segment, said medium (M) RNA segment and said (L) RNA segment.

[0018] According to another aspect, the SBV or the antigen of the SBV is obtainable by the inactivation of SBV or the antigen of SBV, wherein said SBV comprises

- a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 %, preferably at least 99 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7,
- a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2, and/or
- a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3.

[0019] All sequences of the sequence listing are typed in 5' - '3 direction. The sequences of SEQ ID NOs.1 to 3 and 7 code for cDNAs having a positive polarity (+ strand). The term "inverse complementary" means that the sequence is anti-parallel to the

reference sequence.

[0020] Preferably said SBV comprises said small (S) RNA segment, said medium (M) RNA segment and said (L) RNA segment.

[0021] It is understood that the term "RNA segment", as used herein, is equivalent to "genome segment" or "segment", as frequently used in the context of Schmallenberg virus.

[0022] Preferably, the small (S) RNA segment mentioned herein has an RNA sequence that is inverse complementary to a DNA sequence having at least 97.8 %, more preferably at least 98.5 %, even more preferably at least 99 %, still more preferably at least 99.5 % or in particular 100 % sequence identity with the nucleic acid sequence of SEQ ID NO:1, or preferably, the small (S) RNA segment described herein has an RNA sequence that is inverse complementary to a DNA sequence having at least 97.8 %, more preferably at least 98.5 %, even more preferably at least 99 %, still more preferably at least 99.5 % or in particular 100 % sequence identity with the nucleic acid sequence of SEQ ID NO:7.

[0023] Preferably, the medium (M) RNA segment mentioned herein has an RNA sequence that is inverse complementary to a DNA sequence having at least 83 %, more preferably at least 85 %, even more preferably at least 90 %, still more preferably at least 95 % or in particular 100 % sequence identity with the nucleic acid sequence of SEQ ID NO:2.

[0024] Preferably, the large (L) RNA segment mentioned herein has an RNA sequence that is inverse complementary to a DNA sequence having at least 94 %, more preferably at least 96 %, still more preferably at least 98 % or in particular 100 % sequence identity with the nucleic acid sequence of SEQ ID NO:3.

[0025] As used herein, the term "immunogenic composition" in particular refers to a composition that will elicit an immune response in a mammal and/or an insect that has been exposed to the composition. An immune response may include induction of antibodies and/or induction of a T-cell response.

[0026] Sequence identity in the context of the invention is understood as being based on pairwise sequence alignments. For purposes of the present invention, pairwise sequence alignments are done with ClustalW as implemented in Mega5 (K. Tamura et. al., MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol. Biol. Evol. 28, 2731-2739 (2011)), using the default settings (gap opening penalty of 15 and gap extension penalty of 6.66; DNA weight matrix: ClustalW 1.6; Transition weight of 0.5). Sequence identities of the aligned sequences are calculated using BioEdit version 7.0.9.0.

[0027] It is understood that the term "sequence identity to", as used herein, herein, is equivalent to the term "sequence identity with the nucleic acid sequence of". Thus, as mentioned herein, the term "sequence identity to SEQ ID NO:4 or SEQ ID NO:8" is equivalent to the term "sequence identity with the nucleic acid sequence of SEQ ID NO:4 or SEQ ID NO:8", the term "sequence identity to SEQ ID NO:5" is equivalent to the term "sequence identity with the nucleic acid sequence of SEQ ID NO:5", and the term "sequence identity to SEQ ID NO:6" is equivalent to the term "sequence identity with the nucleic acid sequence of SEQ ID NO:6".

[0028] As used herein, it is in particular understood that the term "sequence identity with the nucleic acid sequence of SEQ ID NO:X" is equivalent to the term "sequence identity with the nucleic acid sequence of SEQ ID NO:X over the length of SEQ ID NO: X" or to the term "sequence identity with the nucleic acid sequence of SEQ ID NO:X over the whole length of SEQ ID NO: X", respectively. In this context, "X" is any integer selected from 1 to 8 so that "SEQ ID NO: X" represents any of the SEQ ID NOs mentioned herein.

[0029] In a further preferred aspect of the invention, the SBV mentioned herein comprises

- an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 %, preferably at least 99 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8,
- an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5, and/or
- an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6,

and wherein in particular said SBV comprises said small (S) RNA segment, said medium (M) RNA segment and said (L) RNA segment.

[0030] Preferably, the SBV mentioned herein comprises

- an S RNA segment, characterized in that the S RNA segment has
 - an RNA sequence having at least 97.8 %, more preferably at least 98.5 %, even more preferably at least 99 %, still more preferably at least 99.5 % or in particular 100 % sequence identity to SEQ ID NO:4, or
 - an RNA sequence having at least 97.8 %, more preferably at least 98.5 %, even more preferably at least 99 %, still more preferably at least 99.5 % or in particular 100 % sequence identity to SEQ ID NO:8; and/or
- an M RNA segment, characterized in that the M RNA segment has a RNA sequence having at least 83 %, more preferably at least 85 %, even more preferably at least 90 %, still more preferably at least 95 % or in particular 100 % sequence identity to SEQ ID NO:5; and/or
- an L RNA segment, characterized in that the L RNA segment has a RNA sequence having at least 94 %, more preferably at least 96 %, still more preferably at least 98 % or in particular 100 % sequence identity to SEQ ID NO:6.

[0031] The term "having 100% sequence identity", as used herein, is also understood to be equivalent to the term "being identical".

[0032] Preferably, the inactivated SBV is obtainable by the inactivation of SBV by heat treatment or preferably with a virus inactivating agent, wherein in particular an aziridine compound, most preferably binary ethyleneimine (BEI), is used for the inactivation.

[0033] According to one preferred aspect, BEI is added to the antigen in a final concentration of 10 mM or less, wherein it has been surprisingly found that a final concentration of less than 4 mM is sufficient for the inactivation of the antigen. Thus, BEI is preferably added to a final concentration of less than 4 mM to the antigen, more preferably to a final concentration of 0.5 to 3.5 mM, most preferably to a final concentration of 1 to 3 mM.

[0034] After the addition of BEI, the mixture is preferably kept in agitation for 48 h or less, preferably for 24 h or less, most preferably for between 6 h and 18 h, such as e.g. for 12 h. The temperature of the mixture while the mixture is being agitated is preferably 37+/-5°C, most preferably 37+/-1°C.

[0035] Further, it has been found that only one inactivation step, e.g. by adding BEI to the antigen, is sufficient for the inactivation of the antigen.

[0036] After the inactivation procedure, the residual virus inactivating agent is preferably neutralized by adding a neutralizing agent to the mixture, in particular in a molar excess in comparison to the amount of virus inactivating agent added to the antigen. If an aziridine compound is used for the inactivation, then preferably a nucleophile which opens the three-membered ring is used for the neutralization. BEI is preferably neutralized by the addition of sodium thiosulphate, in particular in a 1.1 to 10 fold molar excess, most preferably in a 2 to 8 fold molar excess in comparison to the amount of BEI added to the antigen.

[0037] In a preferred aspect, the immunogenic composition of the invention comprises an amount of SBV which is equivalent to a virus titre of at least about 10^5 TCID₅₀/mL per dose, preferably between 10^5 to 10^7 TCID₅₀/mL per dose, more preferably about 10^6 TCID₅₀/mL per dose.

[0038] Surprisingly, it has been found that an immunogenic composition of the invention comprising an amount of SBV which is equivalent to a virus titre of less than 10^5 TCID₅₀/mL per dose, preferably less than 10^5 TCID₅₀/mL per dose, is sufficient to prevent SBV RNAemia in an animal, in particular in sheep.

[0039] Thus, the immunogenic composition of the invention preferably comprises an amount of SBV which is equivalent to a virus titre of less than $10^{5.5}$ TCID₅₀/mL per dose, preferably less than 10^5 TCID₅₀/mL per dose, more preferably between 10^3 to 10^5 TCID₅₀/mL per dose, most preferably between 10^4 to 10^5 TCID₅₀/mL per dose, in particular for use in a method for inducing an immune response against SBV and/or for preventing or reducing viremia or malformations induced by SBV and/or for preventing or reducing the transmission of SBV, preferably in sheep.

[0040] "RNAemia" as described herein is in particular understood as the detection of RNA (e.g., by nucleic acid sequence-based amplification or reverse transcription PCR) in a sample of an animal, in particular in samples of plasma, serum or whole blood.

[0041] It is thus in particular understood, according to the invention, that viremia induced by SBV goes hand in hand or is accompanied, respectively, with SBV RNAemia in a sample of blood serum of an animal. Hence, viremia induced by SBV can be examined by detecting specific SBV RNA in the serum of animals.

[0042] In another preferred aspect, the immunogenic composition of the invention contains SBV having a pre-inactivation titre of at least about 10^6 SBV particles per milliliter, preferably between 10^6 to 10^8 TCID₅₀/mL SBV particles per milliliter, more preferably about 10^7 SBV particles per milliliter.

[0043] The term "pre-inactivation titre", as used herein, in particular refers to the amount of suspended SBV which is inactivated.

[0044] In particular, the immunogenic composition of the invention, further contains one or more pharmaceutically acceptable carriers or excipients, wherein said one or more pharmaceutically acceptable carriers or excipients are preferably selected from the group consisting of solvents, dispersion media, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, and adsorption delaying agents.

[0045] In a particular preferred aspect, the immunogenic composition of the invention further contains one or more adjuvants, preferably aluminium hydroxide and/or saponin, e.g. Alhydrogel and/or Quil-A, wherein a combination of aluminium hydroxide and saponin is most preferred.

[0046] Another aspect concerns the immunogenic composition of the invention for use as a medicament, preferably as a vaccine.

[0047] A further aspect relates to the immunogenic composition of the invention for use in a method for inducing an immune response against SBV and/or for preventing or reducing viremia or malformations induced by SBV and/or for preventing or reducing the transmission of SBV.

[0048] This aspect in particular relates to the immunogenic composition of the invention for use in a method for inducing an immune response against SBV in a ruminant and/or insect and/or for preventing or reducing viremia in a ruminant and/or insect and/or for preventing or reducing malformations induced by SBV in a ruminant fetus or newborn and/or for preventing or reducing the transmission of SBV by arthropod vectors, preferably insects and/or for preventing or reducing the transmission of SBV from the pregnant animal (the mother) to the fetus.

[0049] As used herein, the term "inducing an immune response" to an antigen or composition is the development of a humoral and/or cellular immune response in an animal to an antigen present in the composition of interest.

[0050] The term "prevention" or "reduction" or "preventing" or "reducing", respectively, as used herein, means, but is not limited to a process which includes the administration of a SBV antigen, namely of the antigen of SBV according to the invention which is included in the composition of the invention, to an animal, wherein said SBV antigen, when administered to said animal elicits or is able to elicit an immune response in said animal against SBV. Altogether, such treatment results in reduction of the clinical signs of a disease caused by SBV or of clinical signs associated with SBV infection, respectively. More specifically, the term "prevention" or "preventing", as used herein, means generally a process of prophylaxis in which an animal is exposed to the immunogenic composition of the present invention prior to the induction or onset of the disease process caused by SBV.

[0051] Herein, "reduction of clinical signs associated with SBV infection" means, but is not limited to, reducing the number of infected subjects in a group, reducing or eliminating the number of subjects exhibiting clinical signs of infection, or reducing the severity of any clinical signs that are present in the subjects, in comparison to wild-type infection. For example, it should refer to any reduction of pathogen load, pathogen shedding, reduction in pathogen transmission, or reduction of any clinical sign symptomatic of SBV infection, in particular of the transmission of SBV from the mother to the fetus or of the malformations induced by SBV in a ruminant fetus or newborn. Preferably these clinical signs are reduced in subjects receiving the composition of the present invention by at least 10% in comparison to subjects not receiving the composition and may become infected. More preferably, clinical signs are reduced in subjects receiving the composition of the present invention by at least 20%, preferably by at least 30%, more preferably by at least 40%, and even more preferably by at least 50%.

[0052] The term "reduction of viremia induced by SBV" (or, alternatively, "reduction of RNAemia induced by SBV") means, but is not limited to, the reduction of SBV virus entering the bloodstream of an animal, wherein the viremia level, i.e. the number of SBV RNA copies per mL of blood serum or the number of plaque forming colonies per deciliter of blood serum, is reduced in the blood

serum of subjects receiving the composition of the present invention by at least 50% in comparison to subjects not receiving the composition and may become infected. More preferably, the viremia level is reduced in subjects receiving the composition of the present invention by at least 90%, preferably by at least 99.9%, more preferably by at least 99.99%, and even more preferably by at least 99.999%.

[0053] As used herein, the term "viremia" is particularly understood as a condition in which Schmallenberg virus particles reproduce and circulate in the bloodstream of an animal, in particular of a mammal or of an insect.

[0054] The term "animal", as used herein, in particular relates to a mammal or to an insect.

[0055] Preferably, the mammal as mentioned herein is a ruminant. More preferably, the ruminant as mentioned herein is selected from the group consisting of cattle, sheep, goats, deer, elk, giraffes, bison, moose, yaks, water buffalo, camels, alpacas, llamas, antelope, pronghorn, and nilgai. Most preferably, the mammal or ruminant as mentioned herein is selected from the group consisting of cattle, sheep and goats.

[0056] The insect, as mentioned herein, is preferably selected from the group consisting of midges, in particular *Culicoides spp.*, biting flies and mosquitoes.

[0057] Further, the invention provides a vaccine composition for the treatment or prevention of SBV or for the prevention or reduction of the viremia of malformations induced by SBV and/or for the prevention or reduction of the transmission of SBV, wherein the vaccine comprises the immunogenic composition of the invention.

[0058] In particular, the invention provides a vaccine composition, which comprises the immunogenic composition of the invention, for use in a method for inducing an immune response against SBV in a ruminant and/or insect and/or for preventing or reducing viremia in a ruminant and/or insect and/or for preventing or reducing malformations induced by SBV in a ruminant fetus or newborn and/or for preventing or reducing the transmission of SBV by arthropod vectors, preferably insects.

[0059] The term "malformations", as used herein, in particular relates to a malformation selected from congenital malformation of the vertebral column (Kyphosis, lordosis, scoliosis, torticollis) and/or of the skull (macrocephaly, brachygnathia inferior), variable malformations of the brain (hydracephaly, porencephaly, cerebellar hypoplasia, haploplasia of the brain stem) and of the spinal cord, malformations and/or stiffening of fore and/or hind legs. More particular, the term "malformations" relates to malformations in lambs, kids and calves.

[0060] The disclosure also provides a method for the production of infectious SBV, comprising the steps of

- infecting cells, preferably mammalian or insect cells, with a SBV,
- cultivating the infected cells,
- harvesting the SBV produced by said cells.

[0061] The term "infecting", as used herein, in particular refers to the process of contacting cells with SBV, such as by inoculation.

[0062] Said infection of the cells with a SBV in particular includes attachment of the virus to a cell, entry of the virus into the cell, uncoating of the virion in the cytoplasm, replication and transcription of the viral genome, expression of viral proteins and assembly and release of new infectious viral particles.

[0063] The term "cultivating", as used herein, is particularly directed to the maintenance and preferably the growth of cells under suitable conditions.

[0064] The term "harvesting", as used herein, in particular refers to the taking of cell supernatant which contains viral particles, such as by centrifugation of a container containing a culture of virus infected cells and subsequent decantation of the cell supernatant.

[0065] Surprisingly, it has been found that SBV remains infectious, and thus also remains its antigenic potential, when it is alternately passaged between insect cells and mammalian cells.

[0066] Thus, the disclosure in particular concerns a method for the production of preferably infectious SBV, in particular the above-mentioned method, wherein the SBV is passaged alternately between insect cells and mammalian cells.

[0067] Hence, the method for the production of infectious SBV according to the disclosure in particular comprises the steps of:

1. (a) infecting insect cells with a SBV,
2. (b) cultivating the infected cells of step (a),
3. (c) harvesting the SBV produced by said cells in step (b),
4. (d) infecting mammalian cells with the SBV harvested in step (c),
5. (e) cultivating the infected cells of step (d), and
6. (f) harvesting the SBV produced by said cells in step (e)

or comprises the steps of

- (d) infecting mammalian cells with a SBV,
- (e) cultivating the infected cells of step (d),
- (f) harvesting the SBV produced by said cells in step (e)
- (g) infecting insect cells with the SBV harvested in step (f),
- (h) cultivating the infected cells of step (g), and
- (i) harvesting the SBV produced by said cells in step (h).

[0068] In this regard, the numeration of the steps (d)-(i) is equivalent to the numeration (a')-(f') and has been chosen for reasons of clarity in view of the further steps described herein (starting with the step "(j)").

[0069] Preferably, the method for the production of SBV of the disclosure comprises the steps of:

1. (a) infecting insect cells with a SBV,
2. (b) cultivating the infected cells of step (a),
3. (c) harvesting the SBV produced by said cells in step (b)
4. (d) infecting mammalian cells with the SBV harvested in step (c),
5. (e) cultivating the infected cells of step (d),
6. (f) harvesting the SBV produced by said cells in step (e)
7. (g) infecting insect cells with the SBV harvested in step (f)
8. (h) cultivating the infected cells of step (g), and
9. (i) harvesting the SBV produced by said cells in step (h).

[0070] More preferably, the method for the production of infectious SBV according to the disclosure further comprises the steps of

- (j) infecting mammalian cells with the SBV harvested in step (i),
- (k) cultivating the infected cells of step (j), and
- (l) harvesting the SBV produced by said cells in step (k), and optionally
- (m) infecting insect cells with the SBV harvested in step (l),
- (n) cultivating the infected cells of step (m), and
- (o) harvesting the SBV produced by said cells in step (n).

[0071] Thus, in one aspect, the method for the production of infectious SBV according to the disclosure comprises the steps of

1. (a) infecting insect cells with a SBV,
2. (b) cultivating the infected cells of step (a),
3. (c) harvesting the SBV produced by said cells in step (b)
4. (d) infecting mammalian cells with the SBV harvested in step (c),
5. (e) cultivating the infected cells of step (d),
6. (f) harvesting the SBV produced by said cells in step (e)
7. (g) infecting insect cells with the SBV harvested in step (f)
8. (h) cultivating the infected cells of step (g),
9. (i) harvesting the SBV produced by said cells in step (h)
10. (j) infecting mammalian cells with the SBV harvested in step (i),
11. (k) cultivating the infected cells of step (j), and
12. (l) harvesting the SBV produced by said cells in step (k),

and optionally

(m) infecting insect cells with the SBV harvested in step (l),

(n) cultivating the infected cells of step (m), and

(o) harvesting the SBV produced by said cells in step (n).

[0072] The insect cells used in the method for the production of SBV of the disclosure are preferably KC cells.

[0073] As mammalian cells preferably BHK cells, in particular BHK-21 cells, are used in the method for the production of SBV according to the disclosure.

[0074] Most preferably, in the method for the production of SBV according to the disclosure the insect cells are KC cells, and the mammalian cells are BHK cells, in particular BHK-21 cells.

[0075] Further, the disclosure also comprises the SBV obtainable by the method for the production of SBV according to the disclosure.

[0076] The disclosure further provides a method for the production of inactivated SBV or of an immunogenic composition of the disclosure comprising the steps of:

(A) infecting cells with a SBV, wherein the cells are in particular monkey kidney cells, preferably Ma104 cells or Ma104-AK cells, or wherein the cells are BHK cells, preferably BHK-21 cells,

(B) cultivating the infected cells,

(C) harvesting the SBV produced by said cells, and

(D) inactivating said SBV by heat treatment or with a virus inactivating agent

[0077] If preferably Ma104 cells or Ma104-AK cells are used in the method for the production of inactivated SBV or of the immunogenic composition of the disclosure, this has the advantage that adverse reactions, in particular allergic reactions, can be reduced or minimized if the inactivated SBV or the immunogenic composition produced by said method is administered to an animal.

[0078] In particular, it is preferred if in step (A) of the method for the production of inactivated SBV or of the immunogenic composition of the disclosure the cells are infected with a SBV obtainable by the method for the production of SBV of the disclosure.

[0079] The disclosure thus also provides the combination of (i) the method of producing an infectious SBV of the disclosure and (ii) the method for the production of inactivated SBV or of the immunogenic composition of the disclosure, wherein said methods are performed subsequently.

[0080] Preferably, in the method for the production of infectious SBV of the disclosure and/or in the method for the production of inactivated SBV or of the immunogenic composition according to the disclosure, the cells are infected with SBV at an MOI of 0,00001 - 0,01, preferably at an MOI of 0,0001 - 0,001.

[0081] In particular it is preferred, if in the method for the production of SBV according to the disclosure and/or in the method for the production of inactivated SBV or of the immunogenic composition of the disclosure, the cells are cultivated in a medium containing 1-10 % FCS, more preferably containing 2-6 % FCS, and/or if the cells are cultivated at a temperature of 25-38°C, preferably of 36-38°C, more preferably of about 37°C. It is also possible to cultivate the cells in the absence of FCS.

[0082] Also, the disclosure comprises SBV obtainable by the method for the production of inactivated SBV or of the immunogenic composition of the disclosure, and, moreover, the disclosure also provides inactivated SBV obtainable by the combination of (i) the method of producing an infectious SBV of the disclosure and (ii) the method for the production of inactivated SBV or of the immunogenic composition of the disclosure, wherein said methods are performed subsequently.

[0083] In another aspect, it is preferred if in the method for the production of infectious SBV of the disclosure and/or in the method for the production of inactivated SBV or of the immunogenic composition of the disclosure, the SBV comprises

- a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 %, preferably at least 99 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7,
- a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2, and/or
- a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3,

and/or wherein said SBV comprises

- an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 %%, preferably at least 99 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8,
- an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5, and/or
- an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6.

[0084] The disclosure also provides a SBV, preferably an isolated SBV, comprising

- a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 %, preferably at least 99 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7,
- a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2, and/or
- a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3.

[0085] The disclosure further provides a preferably isolated SBV, in particular the aforementioned SBV, which comprises

- an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8,
- an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5, and/or
- an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6.

[0086] Also the disclosure comprises a composition of matter obtainable by any of the aforementioned methods, wherein the composition is preferably an immunogenic composition, in particular a vaccine.

[0087] A further aspect of the invention relates to the use of the immunogenic composition of the invention for the preparation of a medicament for treating or preventing SBV and/or treating or preventing viremia or malformations induced by SBV and/or preventing or reducing the transmission of SBV in an animal in need of said treatment.

[0088] Also, the invention provides a method of generating an immune response to SBV in an animal comprising administering to said animal the immunogenic composition of the invention.

[0089] In another aspect, the invention provides a method of treating or preventing SBV or treating or preventing viremia or malformations induced by SBV in an animal in need of said treatment, comprising administering to said animal a therapeutically effective amount of the vaccine composition of the invention.

[0090] The invention further provides a method for inducing an immune response against SBV and/or preventing or reducing viremia or malformations induced by SBV and/or preventing or reducing the transmission of SBV in an animal or a herd of animals comprising the step of administering the immunogenic composition of the invention to an animal in need thereof.

[0091] In the aforementioned methods, the immunogenic composition of the invention or the vaccine of the invention, respectively, is preferably administered in a single dose or more preferably in two doses.

EXAMPLE 1

Details about first SBV isolation

[0092] BHK-21 cells have been extensively used for growth of Orthobyniaviruses. Following this, SBV virus was successfully isolated for the first time using this cell line, by FLI researchers in November 2011. Except for the BHK, *Culicoides variipennis* larvae cells (referred to as KC cells from Collection of Cell Lines in Veterinary Medicine, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany) were used. KC cells were incubated for 10 days with ultrasonically disrupted blood diluted in Schneider's media. The cells were then lysed by freezing and thawing. A monolayer of baby hamster kidney-21 cells (BHK, clone 13) was inoculated with the lysate. The inoculum was removed after 1 hour and replaced by Eagle minimal essential medium (EMEM). A strong cytopathic effect was visible after 5 days, and the culture supernatant tested positive for the novel virus, with a Cq value of approximately 14 in the specific cRT-qPCR (isolate 2) and 3×10^6 TCID₅₀ per ml.

Manufacturing process: General description

[0093] The manufacturing process, as described below, is carried out following standard manufacturing methods, e.g. under conditions of sterility and after verification of correct operation conditions such as air filtration.

Description of manufacturing process:

1. Production of MSV (master stock virus)

[0094] The SBV isolate 2 was used for MSV (Master Stock Virus) production. Roller bottle plated with BHK-21 cells (5×10^7 cells) were infected at moi 0,0001. After 54h of incubation roller bottle is frozen at -20, thawed and centrifugated at 2000g for 5min. Supernatant was collected and aliquots of 1ml were stored at -80C until further process.

2. Production of SBV antigen

[0095] The BHK-21 cells (working cell stock - WCS) are stored frozen in liquid nitrogen. WCS was thawed and expanded on cell culture flasks (T160cm²) using EMEM media and 10% gamma irradiated FCS. Cells were trypsinised using recombinant (non animal origin) trypsin. One T160 flask was trypsinised and resuspended in 150ml of EMEM media containing 2% FCS. This cell

suspension was used to seed one roller bottle (495cm²). Roller bottles containing cell suspension were placed in 37C incubator and roller at 0,5 rpm. Twelve to 16h post plating cells were plated at density 5x10⁷ per bottle. Infection using moi 0,0001 was used. Cells were continuously incubated at 37C and rolled at 0,5 rpm for 50-56h until specific SBV cytopathic effect (CPE) don't reach about 60-70% of cells. At this time point the complete roller bottle flasks were frozen at -20C and thawed in 37C water bath and stored at -80C until further process.

[0096] The virus titration is performed following procedure:

Materials needed

[0097]

1. 1. BHK-21 cells (clone 13)
2. 2. T75 flasks
3. 3. Flat bottom 96 wells plates
4. 4. Flat bottom 48 wells plates
5. 5. Thermo 8-channel matrix pipette + tips
6. 6. Eppendorf 8-channel pipette 50-1250 + tips
7. 7. Reservoir for multichannel pipettes
8. 8. Trypsin+edta
9. 9. Media ZB5
10. 10. Pipettes 5, 10 and 25ml
11. 11. Pipetboy
12. 12. Inverted microscope

Procedure

[0098]

- Highly confluent T75 flask trypsinize and cells nicely resuspend in 20ml of media (10%FCS).
- Add 100ml of media (0% FCS) and mix well
- This cell suspension pours into reservoir for multichannel pipettes
- Use multichannel pipette to fill 100µl of cell suspension into the wells of first 8 columns of 96 wells plates
- Leave plates at 37°C in CO2 incubator for 6-12h to attach
- After this time prepare 48 wells plate and fill 1080µl of serum free media in each well
- In the wells of the first column inoculate 120µl of material for titration
- Using eppendorf8-channel pipette with the program P/M (pipette 120µl and mix 620µl four times) firstly mix the first column where the material is inoculated
- Discard tips
- From the wells of the first column (with the new tips) pipette 120µl into second and mix
- Discard tips
- Repeat this process until you finish the last column
- Using matrix pipette aspirate 800µl from the first row of 48 well plate (which contains serial dilutions of one sample)
- When attaching tips press firmly, but not too strong as the matrix function will not work
- Dispense 100µl in 8 rows of 96wells plate
- Incubate at 37C for period of 3-4 days
- Read results on inverted microscope

3. Vaccine formulations

3.1 Inactivation procedure

[0099] The process of inactivation of the final antigen lasts for a total of 72 hours, and the concentration of BEI used is 15 mM. Final antigen is inactivated by adding BEI 0.1 M at a proportion of 100 ml per liter of antigen being inactivated (final concentration 10 mM). After the addition of the BEI the mixture is homogenized for at least 15 minutes and the pH is verified. After the homogenization process, the mixture is decanted into a sterile container where it is kept in agitation, at 37±1°C, for 24 hours. After 24 hours, a second inactivation of the final antigen is carried out by means of adding BEI 0.1 M at a proportion of 50 ml per liter of antigen being inactivated (final concentration 5 mM). After the second addition of BEI, the process is repeated under the same conditions as described above for the first addition, but maintaining the mixture in agitation for 48 hours.

3.2 Neutralization of residual BEI

[0100] Once the inactivation process has been completed, 1 M sodium thiosulphate solution is added at the proportion of 5 ml per liter of inactivated antigen (final concentration 5 mM), in order to neutralize the BEI. After the mixture has been homogenized, the pH is verified. If necessary, an adjustment is done with hydrochloric acid, to obtain a pH of 7.2±0.2.

3.3 Adjuvants

[0101] Alhydrogel (aluminium hydroxide) and Quil-A (saponin) are used as adjuvants.

4. Proof of concept experiment in cattle.

[0102] Eighteen (18) - 7 month old cattle are used for the experiment. Animals are been divided into four groups with four animals in each group, while other two animals are used as contact controls. All animals are SBV sero-negative at the beginning of experiment. First group (of four animals) is vaccinated with the vaccine dose containing 10^6 SBV TCID₅₀/ml, the second with 10^5 SBV TCID₅₀/ml, third with 10^4 SBV TCID₅₀/ml and finally fourth group is not vaccinated as well as two animals within contact control. Within each group 4 animals are vaccinated by the subcutaneous route (2 mL) and revaccinated 3 weeks later. All animals in the study are challenged two weeks after re-vaccination (challenge dose = 10^7 TCID₅₀ of live virus / animal) except of contact control animals. All non vaccinated animals develop viremia upon SBV challenge, starting at 3 dpi (days post infection) and lasting 2-3 days. Animals vaccinated show significantly lower viremia and reduced to no clinical symptoms compared to non-vaccinated animals after the SBV challenge.

EXAMPLE 2

1. Introduction

[0103] In this study, several inactivated vaccine formulations have been produced and subsequently tested in sheep and cattle regarding their ability to induce neutralising antibodies and to prevent viraemia after experimental challenge infection.

2. Materials and methods

Vaccines

[0104] Five different prototype vaccine formulations were produced (Table 1); all of them were inactivated SBV preparations in aqueous solution. SBV was either grown on two different baby hamster kidney (BHK-21) cell lines (vaccines "BHKCT-HT", "BHK13-HT", "BHK13-LT") or on MA-104 cells (vaccines "MA-HT" and "MA-LT").

[0105] The antigen-concentration was formulated using the infectious titre of SBV before inactivation with binary ethylenimine (BEI) using either a long (using 10 mM of BEI for 72 hours at 37°C) or a short (using 2 mM of BEI for 12 hours at 37°C) protocol.

[0106] Vaccine candidates contained antigen concentration as follows: 6.1 log₁₀ 50% tissue culture infectious doses per ml (TCID₅₀/ml) (MA-HT) or 5.7 log₁₀ TCID₅₀/ml (BHKCT-HT, BHK13-HT, MA-LT) or 4.7 log₁₀ TCID₅₀/ml (BHK13-LT). Saponin and aluminium hydroxide were used as adjuvants (0,125 µg Saponin per 1 ml and 6,65 mg aluminium hydroxide per ml in all vaccine candidate formulations). All formulations were tested for the absence of bacterial contamination and in duplicates for successful inactivation by two subsequent passages in BHK-21 cells. The pH values of each prototype vaccine were adjusted at 6.8-7.2 at 20° C. The vaccines were kept at 4°C until use.

Table 1: Vaccines and animal groups.

Vaccines				Animals	
Name	Cell line	Infectious titre used	Inactivation	Animal group	Animal number
		5.7 log ₁₀			
BHKCT-HT	BHK-21 clone CT	TCID ₅₀ /ml	long protocol	A (sheep)	S01 - S05
				G (cattle)	C01 - C06
		5.7 log ₁₀			
BHK13-HT	BHK-21 clone 13	TCID ₅₀ /ml	short protocol	B (sheep)	S06 - S10
		4.7 log ₁₀			
BHK13-LT	BHK-21 clone 13	TCID ₅₀ /ml	short protocol	C (sheep)	S11 - S15
		6.1 log ₁₀			
MA-HT	MA-104	TCID ₅₀ /ml	short protocol	D (sheep)	S16 - S20
				H (cattle)	C07 - C10
		5.7 log ₁₀			
MA-LT	MA-104	TCID ₅₀ /ml	long protocol	E (sheep)	S21 - S25
				I (cattle)	C11 - C16
unvaccinated control				F (sheep)	S26 - S30
				K (cattle)	C17 - C22

Animals

[0107] Twenty-five SBV-naïve sheep of European domestic breeds (7 - 9 months of age) were assigned to 5 groups of 5 animals each, which were immunised subcutaneously with one of the prototype vaccines (see table 1). Another 5 sheep were kept as unvaccinated controls. Male and female animals were distributed equally.

[0108] In addition, 22 SBV antibody-negative female Holstein-Friesian cattle were assigned to four groups of four (group H) or six animals (groups G, I and K) each. Animals in group G, H and I were immunised subcutaneously with vaccines BHKCT-HT, MA-HT and MA-LT, respectively. Cattle in group K were kept as unvaccinated controls. On the day of the first vaccination, the animals were between 8 and 12 months of age.

[0109] In each case, the animals were vaccinated twice three weeks apart and three weeks after the second vaccination both vaccinated and control animals were inoculated with 2 x 0.5ml of an SBV field strain that was only passaged in the natural host. During the entire study, rectal body temperatures were measured daily, and the animals were examined for clinical signs by veterinarians.

Sampling, real-time RT-PCR and serology

[0110] Following the first vaccination, serum samples were collected at days 0, 3, 4, 7 and weekly thereafter. After the second

vaccination, serum samples were taken in weekly intervals. Following challenge infection, serum samples were taken daily during the first eight days and on days 14 and 21. Samples of spleen, tonsils, and mesenteric and mandibular lymph nodes were taken at autopsy on days 22 - 29 after challenge infection and homogenized in 1 ml MEM.

[0111] RNA from serum and tissue samples taken at autopsy was extracted using the MagAttract Virus Mini M48 Kit for automated extraction (Qiagen, Germany) according to the manufacturer's recommendations. SBV genome loads were determined by a reverse transcription real-time PCR (RT-qPCR) (7) with an external standard based on the S genome segment. Furthermore, serum samples were analyzed with a commercially available SBV antibody ELISA (ID Screen® Schmallingberg virus Indirect, IDvet, France) using the recommended cut-off of 70% relative optical density compared to the positive control, and in a standard micro-neutralisation assay.

3. Results

Clinical observations and post-mortem examinations

[0112] Following the first vaccination with the vaccine prototypes no adverse side effects were observed; none of the animals showed fever or any other clinical sign. After the second vaccination one cattle immunised with vaccine MA-HT (group H) developed a low-grade swelling at the injection site for 2 days.

[0113] After the challenge infection, one unvaccinated cattle developed fever on day 3, another showed mild diarrhoea for three days. One animal out of group I had nasal discharge for one day.

[0114] Autopsy of the animals did not reveal any significant gross lesions. The mesenteric lymph nodes of all but one (S30) unvaccinated animals were PCR-positive; on average 2.86×10^3 genome copies per mg (copies/mg) were detected. In addition, SBV RNA was found in the mandibular lymph nodes of 3 out of 5 unvaccinated sheep (S27 - S29) and of all control cattle (average 2.68×10^1 copies/mg), the tonsils of S27 - S29 and C18 - C20 (average 9.90×10^1 copies/mg), and spleens of 4 out of 5 unvaccinated sheep (S26 - S29; average 4.57×10^3 copies/mg) and of two control calves (C17, C21; average 1.40×10^1 copies/mg). No viral RNA was detected in any of the vaccinated animals.

Antibody response

[0115] On the day of the first vaccination, all animals were negative in both serological assays.

[0116] Before challenge infection, no antibodies could be detected in the unvaccinated animals. Three weeks after infection all but one (S30) control sheep and cattle scored positive in the neutralisation assay. Antibodies were found in cattle and in 2 out of the 5 unvaccinated sheep (S26, S29) by ELISA as well. Despite an increasing sample OD relative to the positive control OD value (S/P) both the control sheep S27 and S28 scored negative in the ELISA.

[0117] Three weeks after the first immunisation with vaccine BHKCT-HT, BHK13-HT or BHK13-LT (SBV grown on BHK cells), all sheep and cattle were negative in the ELISA, while in S07, S08, S10 (BHKCT-HT), and S04 (BHK13-HT) low antibody titres were detected in the neutralisation assay. Following the second vaccination antibodies were detected in at least one serological assay, in most cases a considerable increase of neutralising antibodies was seen. Three weeks after challenge infection 8 out of 15 sheep (S04, S06, S07, S09, S10, S11, S12, S15) and 5 out of 6 cattle (C01 - C05) were positive in both assays, 7 sheep (S01 - S03, S05, S08, S13, S14) and the remaining cattle (C6) were positive in the neutralisation test only, and S15 in the ELISA assay only.

[0118] After one immunisation with vaccines MA-HT or MA-LT (SBV grown on MA-104 cells), all cattle and all but two sheep scored negative in both serological assays. S22 and S23 had titres of 1:5 and 1:7, respectively, in the neutralisation assay. Following the second vaccination, in S19, S24, C08, and C14 no antibodies could be detected. S16, S21, C07, C09, and C10 scored positive in both serological assays, while the remaining animals were positive in the neutralisation assay only. Three weeks after challenge infection all sheep of group D and 4 out of 5 sheep of group E were positive in the neutralisation assay, in animal S16 antibodies could be detected by the ELISA, and animal S24 was negative in both assays. In all cattle of group H (high titre of SBV) antibodies were detectable by ELISA and neutralisation assay. The same is true for C12 and C13 (group I, low SBV titre), C11, C15, and C16 scored positive only in the neutralisation assay, and in C14 no antibodies could be detected by any

test.

[0119] After the second immunisation an increase of the average neutralising antibody titers were observed, while after challenge infection, most of the neutralisation titers remained constant in all vaccinated groups.

Real-time RT-PCR

[0120] Following the first vaccination SBV genome was not detected in any animal (data not shown), confirming the successful inactivation of SBV with short and long BEI inactivation procedure.

[0121] After challenge infection, all but one (S30) unvaccinated sheep scored positive in the RT-qPCR between day 2 and 4 (S27 - S29) or 5 (S26). In 1 out of 6 unvaccinated cattle (C19) SBV-genome was first detectable on day 1 after infection, the other 5 calves scored positive on day 2 for the first time. SBV genome remained detectable until day 5 (C17, C19 - C21), 6 (C22) or 7 (C18). Three out of 6 cattle immunised with vaccine MA-LT (C12, C 13, C16) were positive in the RT-qPCR on day 3, while the animals vaccinated with MA-HT vaccines did not develop RNAemia (RNA in the blood) upon challenge.

[0122] In serum samples taken from all vaccinated sheep, from control sheep S30, and from all cattle of groups G and H (high titer vaccine groups), viral RNA could not be detected following challenge infection.

4. Conclusion

[0123] Five different inactivated vaccine formulations have been developed and were subsequently tested in cattle and sheep. In the experiments none of the animals showed significant adverse effects and all of the animals seroconverted upon vaccination. Furthermore, majority but not all the animals developed detectable neutralizing SBV antibodies levels upon vaccination. Importantly, upon challenge infection, RNAemia was completely prevented by four prototype vaccines and considerably reduced by the fifth. Those data suggest that protection from virus infection is only partially mediated by neutralizing antibodies and that additional still undetermined mechanisms, most likely associated with cellular immunity, essentially contributed to virus clearance upon SBV challenge. The two major characteristics of inactivated vaccines are (i.) the complete inactivation of the infectious virus, which was demonstrated by cell culture passages and the missing RNAemia after the first immunisation, and (ii.) the induction of protective immunity. Although neutralising antibodies were not detected in every vaccinated animal prior to challenge infection, RNAemia was completely prevented by four prototype vaccines and considerably reduced by the fifth. The detection of viral RNA in the lymphoreticular system was used as diagnostic tool apart from RNAemia in the present study. In contrast to the controls all vaccinated animals were clearly negative for SBV-RNA in the lymphoid system (in the lymphoid organs at the time of autopsy) like the mesenteric lymph nodes. One of the unvaccinated control sheep showed neither RNAemia, nor RT-qPCR-positive tissue samples, nor seroconversion after challenge infection, the reason for that observation remains unclear. Possible explanations are a failed injection or a status of (natural) resistance to SBV infection.

[0124] Nevertheless, the absence of detectable RNA in most vaccine groups allows to draw the conclusion that, if even no viral genomes can be detected (in the serum), no challenge virus could be transmitted to the foetus.

[0125] Although RNAemia was prevented or markedly reduced by vaccination, antibodies were not detected in every animal prior to challenge infection in every test. Overall, the correlation of ELISA test and neutralisation assay was greater in bovine than in ovine samples, especially after challenge infection of unvaccinated animal.

[0126] The highest levels of antibodies of all sheep groups were detected by neutralisation test after challenge infection of unvaccinated sheep. The same was observed after immunisation with several Rift Valley fever vaccines and subsequent challenge (8), where the applied vaccines, however, did not provide sterile immunity, but only a reduction of viraemia. As opposed to this, the SBV vaccine prototypes characterized in this study prevented RNAemia in sheep completely despite a low level of neutralising antibodies.

[0127] In our study, the titre of neutralising antibodies was influenced by the production cell line and the viral titre prior to inactivation. A dose dependence of the cell culture supernatant used for vaccine preparation was described for AKAV as well, independent whether inactivated or attenuated live vaccines were used (9; 10). At least $10^{5.5}$ TCID₅₀/ml of virus were reported to be necessary for vaccine development. As 2 ml of a vaccine containing 6.1 log₁₀ TCID₅₀/ml virus grown on MA-104 cells

prevented RNAemia completely, but in half of the calves which were immunized with $5.7 \log_{10}$ TCID₅₀/ml viral genome was detectable for one day, a similar minimal dose may be assumed for SBV. However, in vaccines produced on BHK-21-cells, the lower viral titre ($5.7 \log_{10}$ TCID₅₀/ml) prevented RNAemia completely in both animal species, in sheep merely $4.7 \log_{10}$ TCID₅₀/ml were necessary.

[0128] In conclusion, in this proof-of-concept characterization of different vaccine candidates, a high efficacy could be demonstrated for four out of five SBV vaccine prototypes in both major target species. As a result, the development of a killed vaccine against Schmallenberg virus, which is efficacious and safe in cattle and sheep, is demonstrated. The results obtained in this study show that inactivated SBV vaccine can be successfully applied to support efforts for SBV spread control as well as disease prevention in domestic ruminants.

EXAMPLE 3

[0129] In the following, an alternative inactivation procedure and subsequent neutralization process is described, which also allowed the production (the further steps of production were performed in accordance with Example 1) of an effective vaccine for a successful prevention of infection with SBV:

Inactivation procedure

[0130] The process of inactivation of the final antigen lasted for a total of 12 hours, and the concentration of BEI used was 2 mM. Final antigen was inactivated by adding BEI 0.17 M at a proportion of 11.9 ml per liter of antigen being inactivated (final concentration 2 mM). After the addition of the BEI, the mixture was kept in agitation, at $37 \pm 1^\circ\text{C}$, for 12 hours.

Neutralization of residual BEI

[0131] Once the inactivation process has been completed, 1 M sodium thiosulphate solution was added at the proportion of 10 ml per liter of inactivated antigen (final concentration 10 mM), in order to neutralize the BEI.

EXAMPLE 4

[0132] Hereinafter, an alternative production of MSV (master stock virus) is described, which likewise enabled the manufacturing (the further steps of the manufacture process were performed in accordance with Example 1, wherein the inactivation procedure was done as described in Example 3) of an effective vaccine for a successful prevention of infection with SBV:

5. Production of MSV (master stock virus)

[0133] The SBV isolate 2 was used for MSV (Master Stock Virus) production. Roller bottle plated with Ma104-Ak (5×10^7 cells) were infected at moi 0,0001. After 54h of incubation roller bottle is frozen at -20°C , thawed and centrifugated at 2000g for 5min. Supernatant was collected and aliquots of 1ml were stored at -80°C until further process.

6. Production of SBV antigen

[0134] The Ma104-Ak (working cell stock - WCS) are stored frozen in liquid nitrogen. WCS was thawed and expanded on cell culture flasks (T160cm²) using EMEM media and 10% gamma irradiated FCS. Cells were trypsinised using recombinant (non animal origin) trypsin. One T160 flask was trypsinized and resuspended in 150 ml of EMEM media containing 2% FCS. This cell suspension was used to seed one roller bottle (495cm²). Roller bottles containing cell suspension were placed in 37C incubator and roller at 0,5 rpm. Twelve to 16 h post plating cells were plated at density 5×10^7 per bottle. Infection using moi 0,001 was used. Infected cells were continuously incubated at 37C and rolled at 0,5 rpm for 72-96h until specific SBV cytopathic effect (CPE) don't reach about 60-70% of cells. At this time point the complete roller bottle flasks were frozen at -20°C and thawed in 37C water bath

and stored at -80C until further process.

IN THE SEQUENCE LISTING:

[0135]

SEQ ID NO:1 corresponds to the complete genomic sequence of a S segment of an infectious Schmallenberg virus (BH80/11-4),
 SEQ ID NO:2 corresponds to the complete genomic sequence of a M segment of an infectious Schmallenberg virus (BHK80/11-4),
 SEQ ID NO:3 corresponds to the complete genomic sequence of a L segment of an infectious Schmallenberg virus (BH80/11-4),
 SEQ ID NO:4 corresponds to anti-parallel (i.e. complementary and inverse) RNA sequence of SEQ ID NO:1,
 SEQ ID NO:5 corresponds to the anti-parallel RNA sequence of SEQ ID NO:2,
 SEQ ID NO:6 corresponds to the anti-parallel RNA sequence of SEQ ID NO:3,
 SEQ ID NO: 7 corresponds to SEQ ID NO:1, wherein the nucleotide at position 9 is "a" instead of "g", and
 SEQ ID NO: 8 corresponds to the anti-parallel RNA sequence of SEQ ID NO:7 and thus corresponds to SEQ ID NO:4, wherein the nucleotide at position 831 is "u" instead of "c".

[0136] The following clauses that have been disclosed in the application as originally filed are also described herein:

1. 1. An immunogenic composition comprising one or more antigens of the Schmallenberg virus (SBV).
2. 2. The immunogenic composition according to clause 1, wherein the immunogenic composition comprises the SBV.
3. 3. The immunogenic composition according to clause 1, wherein the antigen of SBV or the SBV is inactivated.
4. 4. The immunogenic composition according to clause 1, wherein the SBV comprises:
 - (a) a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7;
 - (b) a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2;
 - (c) a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3; or
 - (d) combinations thereof.
5. 5. The immunogenic composition according to clause 1, wherein the SBV is obtainable by the inactivation of SBV comprising:
 - (a) a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7;
 - (b) a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2;
 - (c) a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3; or
 - (d) combinations thereof.
6. 6. The immunogenic composition according to clause 1, wherein said SBV comprises:
 - (a) an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8;
 - (b) an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5;
 - (c) an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6; or
 - (d) combinations thereof.
7. 7. The immunogenic composition according to clause 3, wherein SBV is inactivated by heat treatment or with a virus inactivating agent.
8. 8. The immunogenic composition according to clause 7, wherein virus inactivating agents is an aziridine compound.
9. 9. The immunogenic composition according to clause 8, wherein the aziridine compound is binary ethyleneimine (BEI).

10. 10. The immunogenic composition according to clause 2, comprising an amount of SBV which is equivalent to a virus titer of at least about 10^5 TCID₅₀/mL per dose
11. 11. The immunogenic composition according to clause 2, wherein the SBV has a pre-inactivation titer of at least about 10^6 SBV particles per milliliter.
12. 12. The immunogenic composition according to clause 1, further containing one or more pharmaceutically acceptable carriers or excipients.
13. 13. The immunogenic composition according to clause 12, wherein said one or more pharmaceutically acceptable carriers or excipients are selected from the group consisting of solvents, dispersion media, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, and adsorption delaying agents.
14. 14. The immunogenic composition according to clause 1, further comprising aluminum hydroxide, saponin or combinations thereof.
15. 15. A vaccine composition for the treatment or prevention according to SBV comprising the immunogenic composition according to clause 1.
16. 16. A vaccine composition for the prevention or reduction of the viremia or malformations induced by SBV comprising the immunogenic composition according to clause 1.
17. 17. A vaccine composition for the prevention or reduction of the transmission of SBV, which comprises the immunogenic composition according to clause 1.
18. 18. A method for the production of SBV, comprising the steps of:
 - (a) infecting cells with a SBV;
 - (b) cultivating the infected cells; and
 - (c) harvesting the SBV produced by said cells.
19. 19. The method for the production of SBV according to clause 18, wherein the SBV is passaged alternately between insect cells and mammalian cells, and wherein the method further comprises the steps of
 1. (a) infecting insect cells with a SBV;
 2. (b) cultivating the infected cells of step (a);
 3. (c) harvesting the SBV produced by said cells in step (b);
 4. (d) infecting mammalian cells with the viral particles harvested in step (c);
 5. (e) cultivating the infected cells of step (d); and
 6. (f) harvesting the SBV produced by said cells in step (e).
20. 20. The method for production of SBV according to clause 19, wherein the method further comprises the steps of:
 - (d) infecting mammalian cells with a SBV;
 - (e) cultivating the infected cells of step (d);
 - (f) harvesting the SBV produced by said cells in step (e);
 - (g) infecting insect cells with the viral particles harvested in step (f);
 - (h) cultivating the infected cells of step (g); and
 - (i) harvesting the SBV produced by said cells in step (h).
21. 21. The method according to clause 18, comprising the steps of
 1. (a) infecting insect cells with a SBV;
 2. (b) cultivating the infected cells of step (a);
 3. (c) harvesting the SBV produced by said cells in step (b);
 4. (d) infecting mammalian cells with the SBV harvested in step (c);
 5. (e) cultivating the infected cells of step (d);
 6. (f) harvesting the SBV produced by said cells in step (e);
 7. (g) infecting insect cells with the SBV harvested in step (f);
 8. (h) cultivating the infected cells of step (g); and
 9. (i) harvesting the SBV produced by said cells in step (h).
22. 22. The method according to clause 21, further comprising the steps of:
 - (j) infecting mammalian cells with the SBV harvested in step (i);
 - (k) cultivating the infected cells of step (j); and
 - (l) harvesting the SBV produced by said cells in step (k).

23. 23. The method according to clause 30, further comprising the steps of:
 - (m) infecting insect cells with the SBV harvested in step (l);
 - (n) cultivating the infected cells of step (m); and
 - (o) harvesting the SBV produced by said cells in step (n).
24. 24. The method according to clause 19, wherein the insect cells are KC cells and the mammalian cells are BHK cells.
25. 25. The method according to clause 24, wherein the mammalian cells are BHK-21 cells.
26. 26. A method for the production of inactivated SBV or of an immunogenic composition according to clause 3, comprising the steps of
 1. (A) infecting cells with a SBV;
 2. (B) cultivating the infected cells;
 3. (C) harvesting the SBV produced by said cells; and
 4. (D) inactivating said viral particles by heat treatment or with a virus inactivating agent.
27. 27. The method according to clause 26, wherein the cells are monkey kidney cells or BHK cells.
28. 28. The method according to clause 27, wherein the monkey kidney cells are Ma104 cells or Ma104-AK cells, and the BHK cells are BHK-21 cells.
29. 29. The method according to clause 26, wherein the cells are infected with SBV at an MOI of 0.00001 - 0.01.
30. 30. The method according to clause 26, wherein the cells are infected with SBV at an MOI of 0.0001 - 0.001.
31. 31. The method according to clause 26, wherein the cells are cultivated in a medium comprising about 0 % FCS.
32. 32. The method according to clause 26, wherein the cells are cultivated in a medium comprising about 1-10 % FCS.
33. 33. The method according to clause 26, wherein the cells are cultivated in a medium comprising about 2-6 % FCS.
34. 34. The method according to clause 26, wherein the cells are cultivated at a temperature of 25-38°C.
35. 35. The method according to clause 26, wherein the SBV comprises:
 - (a) a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7;
 - (b) a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2;
 - (c) a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3; or
 - (d) combinations thereof.
36. 36. The method according to clause 26, wherein said SBV comprises:
 - (a) an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8;
 - (b) an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5;
 - (c) an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6; or
 - (d) combinations thereof.
37. 37. A SBV comprising:
 - (a) a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8 % sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7;
 - (b) a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2 % sequence identity with the nucleic acid sequence of SEQ ID NO:2;
 - (c) a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93 % sequence identity with the nucleic acid sequence of SEQ ID NO:3; or
 - (d) combinations thereof.
38. 38. A SBV comprising:
 - (a) an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8;
 - (b) an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5;
 - (c) an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6; or
 - (d) combinations thereof.
39. 39. A composition of matter obtainable by the method according to clause 26.
40. 40. The composition according to clause 39, wherein the composition is an immunogenic composition.

41. 41. The composition according to clause 39, wherein the composition is a vaccine.
42. 42. A method of generating an immune response to SBV in an animal comprising administering to said animal the immunogenic composition according to clause 1.
43. 43. A method of treating or preventing SBV in an animal in need of said treatment comprising administering to said animal a therapeutically effective amount of the immunogenic composition according to clause 1.
44. 44. A method of treating or preventing viremia or malformations induced by SBV comprising administering to said animal a therapeutically effective amount of the immunogenic composition according to clause 1.
45. 45. A method for inducing an immune response against SBV in a herd of animals comprising the step of administering the immunogenic composition according to clause 1 to such animals in need thereof.
46. 46. A method for preventing or reducing viremia or malformations induced by SBV in a herd of animals comprising the step of administering the immunogenic composition according to clause 1 to such animals in need thereof.
47. 47. A method for preventing or reducing the transmission of SBV in a herd of animals comprising the step of administering the immunogenic composition according to clause 1 to such animals in need thereof.
48. 48. The method according to clause 42, wherein the immunogenic composition is administered in a single dose or in two doses.
49. 49. The method according to clause 43 wherein the immunogenic composition is administered in a single dose or in two doses.
50. 50. The method according to clause 44, wherein the immunogenic composition is administered in a single dose or in two doses.
51. 51. The method according to clause 45, wherein the immunogenic composition is administered in a single dose or in two doses.
52. 52. The method according to clause 46 wherein the immunogenic composition is administered in a single dose or in two doses.
53. 53. The method according to clause 47, wherein the immunogenic composition is administered in a single dose or in two doses.

REFERENCES:

[0137]

1. 1. B. Hoffmann ., M. Scheuch, D. Höper, R. Jungblut, M. Holsteg, H. Schirrmeier, M. Eschbaumer, K. V. Goller, K. Wernike, M. Fischer, A. Breithaupt, T.C. Mettenleiter, M. Beer, Novel orthobunyavirus in Cattle, Europe, 2011. *Emerg. Infect. Dis.* 18, 469-472 (2012).
2. 2. M.-M. Gariglinany et al., Schmallerberg virus in calf born at term with porencephaly, Belgium. *Emerg. Infect. Dis.* 18 (2012), doi: 10.3201/eid1806.120104.
3. 3. M. D. Bowen et al., A reassortant bunyavirus isolated from acute hemorrhagic fever cases in Kenya and Somalia. *Virology*. 291, 185-190 (2001).
4. 4. A. M. Q. King, M. J. Adams, E. B. Carstens, E. J. Lefkowitz, Eds., *Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses*. (Elsevier, San Diego, USA, 2011), pp 725-731.
5. 5. R. M. Kinney, C. H. Calisher, Antigenic relationships among Simbu serogroup (Bunyaviridae) viruses. *Am. J. Trop. Med. Hyg.* 30, 1307-1318 (1981).
6. 6. M. F. Saeed, L. Li, H. Wang, S. C. Weaver, A. D. Barrett, Phylogeny of the Simbu serogroup of the genus Bunyavirus. *J. Gen. Virol.* 82, 2173-2181 (2001).
7. 7. Bilk S, Schulze C, Fischer M, Beer M, Hlinak A, Hoffmann B. Organ distribution of Schmallerberg virus RNA in malformed newborns. *Veterinary microbiology* 2012 Mar 30.
8. 8. Kortekaas J, Antonis AF, Kant J, Vloet RP, Vogel A, Oreshkova N, et al. Efficacy of three candidate Rift Valley fever vaccines in sheep. *Vaccine* 2012 May 14;30(23):3423-9.
9. 9. Kurogi H, Inaba Y, Takahashi E, Sato K, Goto Y, Satoda K, et al. Development of inactivated vaccine for Akabane disease. *National Institute of Animal Health quarterly* 1978 Winter; 18(3-4):97-108.
10. 10. Kurogi H, Inaba Y, Akashi H, Takahashi E, Sato K, Satoda K, et al. Immune response of various animals to Akabane disease live virus vaccine. *National Institute of Animal Health quarterly* 1979 Summer; 19(1-2):23-31.

SEQUENCE LISTING

[0138]

<110> Boehringer Ingelheim Vetmedica GmbH

<120> Schmallenberg virus (SBV) vaccine, methods of production and uses thereof

<130> P01-2825

<160> 8

<170> PatentIn version 3.3

<210> 1

<211> 839

<212> DNA

<213> Schmallenberg virus

<400> 1

```

agtagtgagc tccactatta actacagaaa tatgtcaagc caattcattt ttgaagatgt      60
accacaacgg aatgcagcta catttaaccc ggaggtoegg tatgtggcat ttattggtaa      120
gtatgggcaa caactcaact tcggtgttgc tagagtcttc ttcctcaacc agaagaaggc      180
caagatgggc ctacataaga cggcacaacc aagtgtcgat cttacttttg gtgggggtcaa      240
atttacagtg gttaataacc attttcocca atatgtotca aatcctgtgc cagacaatgc      300
cattacacct cacaggatgt caggatatot agcacgttgg attgctgata catgcaaggc      360
tagtgtcctc aaactagotg aagctagtgc tcagattgtc atgccocttg ctgagggttaa      420
gggatgcacc tgggcccgatg gttatacaat gtatcttgga ttgcaacctg gggccgaaat      480
gttccttgat gcttttgact tctatccact agttattgaa atgcataagg tcctcaagga      540
caatatggat gtaaatttta tgaaaaaagt cctccgccaa cgctatggaa caatgactgc      600
tgaagaatgg atgactcaga aaataacaga aataaaagct gcttttaatt ctgttgagca      660
gcttgccctg gccaaatctg gattctctcc tgctgctaga accttcttgc agcaattcgg      720
tatcaacato taaacctctt catcacagat cttcaatttc cgtgcaatat gtctatgtat      780
tgcacaccat tatactgcaa ggcttctgtt aagatagtta ataagtgag aacactact      839

```

<210> 2

<211> 4373

<212> DNA

<213> Schmallenberg virus

<400> 2

```

agtagtgaac taccacaato aaaatgcttc tcaacattgt cttgatatct aacttagcct      60
gttttagcttt tgcactccca cttaaaggaag gcaactagagg gtctaggtgc ttcotgaatg      120
gcgaactggg taaaactgtt aacacatcaa aggtcgtttc agaattgctgt gtgaaagacg      180
acatatotat cattaaatca atggtggaac attataaato aggagatcgg ttggctgctg      240
taataaaata ttatcgttta tatcaggtga aggattggca ttcttgcaat ccaatttatg      300

```

atgaccaogc	ttcctttatg	atattagata	tagataatac	tggcacatta	atccctaaaa	360
tgcatacatg	cagagttgaa	tgcgaaatag	caactgaataa	agatactggc	gaagttatat	420
tgaattcata	tcgaattaac	cactaccgaa	tctcgggcac	aatgcatgta	tcaggttggc	480
ttaaaaacaa	aattgagatt	cctttggaaa	acacatgcga	atccattgag	gtaacatgtg	540
gattaaaaac	acttaatttt	catgcatggt	tccataccca	taagtcatgc	acccgctatt	600
ttaaaggatc	aatcctgccg	gaattgatga	tcgaatcatt	ttgtacgaat	cttgaattaa	660
tactgctagt	aactttcata	ttagttgggt	ctgtcatgat	gatgatattg	acgaaaacat	720
atatagtata	tgtgttcatt	cctatatatt	atccatttgt	gaaattatat	gcttatatgt	780
acaacaaata	ttttaaatg	tgtaaaaatt	gcctgttagc	agtacatccc	tttacaatt	840
gcccatgcac	atgcatctgt	ggaatgattt	acactaccac	tgaatcactc	aaattgcac	900
gcatgtgtaa	caattgttct	ggctataaag	cattgccgaa	aacaaggaaa	ttgtgtaaaa	960
gtaaaatata	caatatagtg	ctatgtgtga	taacatcact	gatatttttc	tcatttatca	1020
cacctatata	gagtcaatgt	atcgatatag	aaaaactgcc	agacgagtat	attacatgta	1080
aaagagagct	agctaatact	aaaagcctga	caattgatga	cacatatagc	tttatatatt	1140
cctgtacatg	cataattgtg	ttaatattac	ttaaaaaggc	agcaaagtat	atcttgtact	1200
gcaactgcag	cttttgttgt	atggtacatg	aacgacgtgg	attgaagata	atggacaact	1260
ttacaaacaa	gtgcctaaat	tgtgtatgog	cagaaaacaa	gggcttaaca	attcacagag	1320
cctctgagaa	atgtctgttc	aaatttgaat	caagttataa	taggacoggg	ttgataatct	1380
ttatgcttct	gtagtccca	acaattgtaa	tgacgcaaga	aactagtatt	aactgcaaaa	1440
acattcaatc	aactcagctt	acaatagagc	acotgagtaa	gtgcatggca	ttttatcaaa	1500
ataaaacaag	ctcaccagtt	gtaatcaatg	aaataatttc	agatgcttca	gtagacgaac	1560
aagaattaat	aaaaagttaa	aacttgaaot	gtaatgtcat	agataggttt	atttcogaat	1620
ctagtgttat	tgagactcaa	gtttattatg	agtatataaa	atcacagttg	tgccctctcc	1680
aagtgcata	tattttcact	atcaattcag	caagtaacat	acaatggaaa	gcactggccc	1740
gaagtttcac	cttaggagtg	tgcaatacga	atcctcataa	acatatatgt	agatgcttgg	1800
agtcetatgca	aatgtgcaca	tcaaccaaga	cagaccacgc	tagggaaatg	tcaatatatt	1860
atgatggta	tccagatcgc	tttgagcatg	acatgaaaat	aatattgaat	ataatgagat	1920
atatagtccc	tggattaggt	cgagtcttgc	ttgatcaaat	caaacaaaca	aaagactacc	1980
aagctttacg	ccacatacaa	ggtaagcttt	ctcctaaatc	gcagtcaaat	ttacaactta	2040
aaggatttct	ggaatttgtt	gattttatcc	ttggtgcaaa	cgtgacaata	gaaaaaacc	2100
ctcaaacatt	aactacatta	tctttgataa	aaggagccca	cagaaacttg	gatcaaaaag	2160


```

atccaggto c aacaccaata ctggtatgca aatcaccaca aaaagtggta tgctactcac 2220
cacgtggtgt cacacaccca ggagattata tatcatgcaa atctaagatg tataagtggc 2280
catctttagg ggtatacaaa cataatagag accagcaaca agcctgcagc agtgacacac 2340
attgcctaga gatgtttgaa ccagcagaaa gaacaataac tacaaaaata tgcaaaagtaa 2400
gtgatatgac ttattcagaa tcgccatata gtactggaat accatcatgc aacgtgaaga 2460
gatttggatc atgtaatgta aggggtcatc aatggcaaat tgcagaatgc tcaaatggct 2520
tattttacta tgtttcagct aaagcccatt cgaaaactaa cgatataaca ctgtactgtt 2580
tatcagcaaa ttgcctggac ttgcgttatg cattcagatc cagtagttgt tcagatatag 2640
tatgggatac aagttatoga aataaattaa cacctaaatc tattaatcat ccagatatgt 2700
aaaaactacat agcagcgctt cagtcagata ttgcaaatga tttaactatg cactacttta 2760
aaccattaaa aaaccttcca gcaataatto ctcaatacaa aacaatgaca ttgaatgggg 2820
acaaggtatc aaatgggtatt aqaatatgtt atatcgagtc gcacatccct gcaattaatg 2880
gtttatcagc agggattaat attgccatgc caaatggaga aagcctcttt tccattatta 2940
tctatgtcag aagagtaata aataaagcat cgtatcgatt tctatatgaa acaggaccca 3000
caattggaat aaatgccaag cagcaagagg tatgtaccgg gaagtgcoca agcccaatac 3060
cacatcaaga tggttgggtc acattctcaa aggaaagatc aagtaattgg ggctgtgaag 3120
aatgggggtg cttggcaata aatgatgggt gtttatatgg gtcattgcaa gacataataa 3180
ggcctgaata taagatatac aagaagtcta gtattgaaca aaaggatgtt gaagtttgta 3240
taacctatgc ccataatca ttctgcagta ccgttgatgt tctccaaact ttaattagcg 3300
acaggataca attagatata caaacgatc aaatggactc tatgccaaat ataattgcag 3360
tcaagaatgg gaaagtttat gttggagata tcaatgactt aggttcgaca gcaagaatat 3420
gtggctcagt ccaattatat tctgaaggga tcattggatc ggaaccccca aaatttgatt 3480
atgtttgcca tgcattcaat cgtaaagatg tcatccttgc aagatgcttt gataactcat 3540
atcagtcctg tcttctcttg gaacaagata atacattaac tattgcttct accagtcata 3600
tggaagtgca taaaaaagtt tcaagcgtgg gtacaatcaa ttataaaatt atgttagggg 3660
attttgacta caatgcatat tcaacacaag caacagtcac aatagatgag atcagggtgtg 3720
gtggttgta tggtgccct gaaggaaatg cttgcgcact caaattgagt accaatacca 3780
tcgggagttg ttcaataaaa agtaactgcg atacatacat taaaataata gcagtcgac 3840
cgatgcagag cgagtattcc attaaagtaa actgccact agcaacagag acagtttcag 3900
taagtgtgtg ctcagcttct gcttacacaa aacottcaat atctaaaaat caaccaaaaa 3960
ttgttttgaa ttcttagat gaaacatctt acatcgagca acatgataaa aagtgttcta 4020
catggctttg cagagtttat aaagaaggga ttagcgtaat atttcagcct ctatttggca 4080

acctatcttt ctattggaga ctgacaatat atataataat ctctttgatt atgetaatc 4140
tgtttctata catattaata ccactgtgca aacggctaaa aggtttattg gaatacaatg 4200
agagaatata ccaaatggaa aataaattta agtgataago cttataacaa tgagcaatta 4260
taaatgaata aataaaaaa ataaaagata aacaaataac aacatatata tgtggttaca 4320
catatatatg taattattca gctgagaagt ttttcatgtg gtagaacact act 4373

```

<210> 3

<211> 6882

<212> DNA

<213> Schmallenberg virus

<400> 3

agtagtgtac ccctaattac aatcactatg gagacataca agattaacat ttttagagat	60
aggatcaacc agtgtcgaag tgctgaagaa gccaaagaca ttgttgctga tcttctcatg	120
gctagacatg actacttttg tagagaggta tgttattaco tggatatcga attccggcag	180
gatgttccag cttacgacat acttcttgaa tttctgccag ctggcactgc tttcaacatt	240
cgcaattgta caccagacaa ttttatcatt cacaatggca agctttatat cattgactat	300
aaagtatcaa ctgatcatgc atatggtcaa aaaacttatg aaaagtacac ccagatcttt	360
ggagacgcat tgtcagaatt gccgtttgat tttgaagttg tgatcatccg tgctgaccct	420
ctgcgagata ctatccatgt taattcaaat caattcttgg aaatatattg gccgctcaac	480
ataaaccttg attttacttg gttctttaat ttgcgatccc tgatatatga gaaatataag	540
gatgacgaca gattcctaga aattgtgaat caaggtgaat ttaogatgac tggaccctgg	600
attgatgagg ataccccgga gctctattca caccctgtct ttttgaatt ctatgattct	660
ttagatgaga tggctaaact gacattccat gagtctatga catttgatgc aactcgcggt	720
gagaaatgga atcaaaatct acaaaagggt ataaatagat atggcaatga ttataacatt	780
tttgtgaaag aggcgctgc aggaatcttt agatgtgaag ggaactacc aaaccaaatt	840
catgatgaaa tcacaatcgg ttggaatcaa atggttcaaa gagtgtgtac tgagagaaac	900
ctgactcaag atgtcagcaa gcaaaaacca tctattcatt tcatatgggg tcaacctgac	960
gaaacatcaa atgcgacaac accaaaacta atcaagattg caaaagcact ccaaaatatt	1020
tctggcgagt ctacatatat aagcgcattc agagcattgg gtatgcttat ggacttttct	1080
gagaacacag ctttatatga agcacacact agcaaaactaa aaagtatggc aagacagaca	1140
tcgaaaagaa ttgatactaa actggaacca atcaaaatag gcacggcgac aatttattgg	1200
gaacagcagt ttaaaactgga tactgaaata atgaatacaa aagacaaatc acatttgcta	1260
aaagattttc ttggcatagg gggtcacgtg caattttcaa aaaagaocat tgaogatttg	1320
gatactgaca aacctactat attagatttc aacaaaaagg aagtcattga tttttgcaaa	1380

ttccagtatg	aaaatgtaaa	gaaaatacta	tccggagata	ataatctaga	gcgtatagga	1440
tggtattttag	aagaatatgg	tgcaaatatt	gcattcatgtt	caaaggatac	atgggatcag	1500
attaaccaga	tagggaagtc	aaattactgg	gcttggtatta	aagatttttc	agtcttgatg	1560
aaaaatatgt	tggcagtttc	tcaatataat	aggcacaata	ctttctgtgt	agtggttgt	1620
gcaacaata	atctgtttgg	gtttgtaatg	ccttcttctg	atattaaagc	aaagcgatcc	1680
acacttgttt	acttcttagc	tgtgttgcat	tctactcttc	agaatgtgat	gcaccacggt	1740
gcattgcgatg	cgacatttaa	aactgggttc	aaatacctta	gtatctctaa	aggaatgcgt	1800
ttagataaag	aacgatgtca	acgcatagtt	agttcacccg	gactttttat	gttgactaca	1860
ttgatgtttg	caggagacaa	tccgacactc	aatttgactg	atgtcatgaa	ttttacattc	1920
cacacttccc	tgtctataac	caaagctatg	ctgtcattga	cagaaccatc	aagatatatg	1980
ataatgaatt	cattagccat	atccagtcct	gttagagatt	atatagcaga	aaaatttggc	2040
ccttatacaa	agaccagctt	ctctgtagta	atggcaaaact	tgattaaaag	gggagtgtat	2100
atggcatata	atcaaagaga	taaagtagac	atgaggaata	tctgcctaac	agattatgaa	2160
ataactcaaa	aagggtgtgag	agataacaga	gacctatcat	caatctgggt	tgaaggctat	2220
gtatcactaa	aagaatatat	taaccaaaata	tatctacat	tttacttcaa	ttcaaaaggt	2280
ttgcctgaaa	agcatcatgt	tatgatagat	ctggctaaga	caatcttaga	tatagaaagg	2340
gaccagagat	taaatatccc	aggaatatgg	tctacaacac	ctagaaaaca	aactgcaa	2400
ttaaatataa	ctatctatgc	agttgcaaaa	aatctaataa	tggacaactgc	tagacataat	2460
tatattagat	cacggataga	aaacacaaac	aacttaataa	gatcgatatg	cactatttct	2520
acattcacca	gctotaaatc	atgtattaaa	gtaggcgact	ttgagaaaga	aaaaagctca	2580
gcaacaaaaa	aggctgcaga	ttgcatgtca	aaagagataa	agaagtatac	aattgcaaac	2640
ccagaatttg	ttgatgaaga	gttactaaat	gcaactataa	gacatttcacg	ctatgaagac	2700
ttaaaaaaag	caatcccgaa	ttatattgac	attatgtcaa	ctaaagtatt	tgattctctg	2760
taccagaaaa	taaaaaggaa	ggagatagat	gataaaacca	ctgtgtatca	tatactctct	2820
gctatgaaga	atcacacaga	ttttaagttt	acattcttta	acaaaggcca	aaaaacagca	2880
aaggataggg	aatattctgt	aggcgaattt	gaggcaaaaa	tgtgcttgta	tttagtgag	2940
aggatatcta	aagaacgctg	taagttgaat	ccagatgaga	tgattagtga	accaggcgat	3000
tctaaattga	aaaaattaga	agagcttgca	gagctctgaa	tacgattcac	agcagcaact	3060
atgaaacaga	tcaaagaagc	ctatttagca	gaaatgggag	aagcaagcca	tatgatcgca	3120
tataaaccac	attctgttaa	gattgaaatc	aatgcagaca	tgtcaaaatg	gagtgcccaa	3180
gatgttttat	tcaaatattt	ctgggtgttt	gcattagatc	ccgcacttta	tctgcaagaa	3240

aaagaaagga tattgtactt cctatgcaat tatatgcaaa aaaagctaatt tctgcctgat	3300
gaaatgctct gtagatcct tgaccaacgt atcaaacatg aggatgatat aatatatgaa	3360
atgaccaatg gcttatcgca aaattgggtc aatattaaac ggaactggct gcaggggaat	3420
ctcaattaca caagtagcta cctacattca tgttctatga atgtttataa ggatattcta	3480
aagagagcag ccactttact agaaggggaa gttttagtca attctatggt tcattctgat	3540
gacaatcaca cttcaatagt gatgatccaa gataaattag atgatgatat tgttattgaa	3600
ttttctgcaa aactatttga aaaaatatgt ctaacttttg gaaatcaagc aaatatgaag	3660
aaagacatata taacaaattt cataaaggag ttogtttcac tttttaatat ttatggtgag	3720
ccattttctg tttatggtog ctttattttg acatctgttg gcgattgtgc tttctctgga	3780
ccatgatgag atgttgccag taggttgtct gcaacgcaga cagcaattaa gcattggagca	3840
cctccatcac ttgcatggac tgctattgca ttaactcagt ggataacaca tagcacatat	3900
aacatgcttc caggccaatt caatgatcct acttcatctt taacctagtca tgatagattt	3960
gagctgccta tagaattgtg tggcttaata aattcagaat taccactat agctatagca	4020
ggtttggaag cagataatct aagttattta gttaggttat caaaaagaat gtccctata	4080
catctttgoc gtgaaccaat ccagcatcaa tatgagaata tacatacatg ggatataagt	4140
aaactgacac aatgtgatat tttcagactt aagcttttaa gatacatgac gttagactca	4200
actatgtcat ctgatgatgg aatgggcgaa actagtgaat tgagatctag gtctctctg	4260
acaccaagaa aattcactac tgcaagttog ttatctagat tgcattcata tgctgattat	4320
caaaaaacaa tacaagacca acagaaaatt gaagaattat ttgaatatat tatagccaac	4380
cctcaactat tggttacaaa aggtgagact tgtgaagagt tctgtatgtc tgtattgttc	4440
agatacaaca gtcgtaaatt taaagaatca ttgtctattc aaaaccagc tcagctcttc	4500
atagaacaag tattgtttgc aaataaacca atgatagact atacaagtat tcatgatagg	4560
ttgtttggta tacaagatga cccaaatata aatgatgcta catgtattat tggcaagaag	4620
acttttgttg aaacatatca gcaataaaaa attgatgtag aaaaatttac acttgatgta	4680
gaggatataa agacgatata tagcttctgt ataatgaacg accctatatt agttgcttgt	4740
gcaaacaact tgttaatttc aatacaggga gtggagatgc aacgattggg tatgacatgc	4800
tgttatatgc cggagattaa gagccttaa gtaatttacc atagtcctgc tctogtatta	4860
cgtgcttatg taacagataa ctatgagcaa aaagggatgg agccagatga aatgoggaga	4920
gatatatatc atttagaaga atttatagag aagacaaaat tgaggacaaa tatgcaaggg	4980
agaattgcaa ataattgaaat taagttaatg aagcgagatt tgaatttga agtgacaggaa	5040
ttgactaaat tctatcagat ctgttatgaa tatgtgaaat caacagaaca caaaattaaa	5100
atattcatoc ttccaaaaaa ggcttacct cccattgatt tctgtcatt agtaacaggt	5160

```

aatctgatat cagacaacaa atggatgggtt gttcactatt taaaacaaat aactgtccca 5220
gcaaagaagg cacaatatagc cacatctata gatctggaaa tacaatatagc ctacgaatgt 5280
ttcaggotaa ttgcacattt tgctgatatg ttcctaaatg atgactocaa aaaagcttat 5340
attaatgcaa ttattaacac atatacatagc aaggatgttc aagtatccag tctctacaag 5400
aaaaatcaaaa attcgagact acgttcaaaa attataccat tattatatca cctgggagat 5460
ttgcaacaaa tagacgttga cagatttgat gcagaaaaag cagaagagca gatcacatgg 5520
aataactggc aaacatctcg agaatttact actgggtccaa ttgatctatc aatcaaaggt 5580
tatggagcgt caataaggat cgtagggtgag gacaacaagc ttacagctgc agaaatgcaa 5640
ttgtcaagag tgagaagtga tatagtatca aggcattgagc aggccttatt gaacaaacct 5700
catgggctaa aattagagaa aatggaacca gtgactgac taaatcctaa attatggat 5760
attgcatacc aattgcgtga gaaaaagcgg tatcactatg gggctcttag tacatcttat 5820
atagaagagc ataactcaag gatagaagca tctcggatac gtaagactaa taaatggata 5880
ccagtttgcc ctattgctat atcaaaacaa tcatctgatg gaaagcctag tcttgcaaaa 5940
atccctatgt taaatatgtg ggagattaaa tttacaaaac tacagattgc agtagatgat 6000
catgcaatga ttaggaaaag ccattttagt aagatgggtg tctttgatgg ccacccata 6060
cagagcgggt gcattgacat tggaaaagctt atgaagaacc aaaatattct caatttgagg 6120
ttagataata tacagagtat aacattatta gatctgtgac gcatattttc atgccgaggg 6180
tctaaagtgg atcaagatgc atttgaattc ttatctgatg aacctttgga tgaagatgtt 6240
attgatgaat tagatagctc acctgcatta gtggtatctt acacaagaa atcaacccaa 6300
tccaatagtt tcaaaaatgt tatagttaga gcattgataa gagaatgtga tatatttgaa 6360
gatataatgg acataacaga cgatggatcc acatctgata gcaatctaga ggtgtagaa 6420
aacttaacat ggatttttaa tatgctcgca acaaatcagt ggtctacaga actgtagca 6480
tgcatacaca tgtgtttata tcgcaatgag atggatcata tctatcacia tttcaagtt 6540
ccagaaatat ttgtcgacaa tccaatctca ttaaatgtaa agtgggatga agtaattatg 6600
ttcttaacaa tactgcgaga cagagattac aaatttgagc catgggtgtc tatactgaat 6660
cattccttaa ctaaaactat agagtatgct taaaaaaga tggaaagga gaggaagcag 6720
aatcaacag gcataacaa attcttaaag ggtaaaaaa tgggtggcag atcaaagttt 6780
gatttccagt agcttgatct taaataatac ataactcttg ccccaaatct gtattatata 6840
aataattcta aagtagtttc atgtaattag gggcaacta ct 6882

```

<210> 4

<211> 839

<212> RNA

<213> Schmallenberg virus

<400> 4

```

aguaguguu uccacuuaa uacuaucua acagaagccu ugcauuuaa uggugugcaa 60
uacauagaca uauugcacgg aaauugaaga ucugugaaga agagguuuag auguugauac 120
cgaauugcug caagaagguu cuagcagcag gagagaaucc agauuuggcc caggcaagcu 180
guccaacaga auuaaaagca gcuuuuuuuu cuuuuuuuu cuagaucauc cauucucag 240
cagucuuugu uccauagcgu uggcggagga cuuuuuuucu aaaaauuaca uccauuuugu 300
ccuugaggac ccuugcauu ucaauaacua guugauagaa gucaaaagca ucaaggaaaca 360
uuugcggccc agguucaaau ccaagauaca uuuaauaacc aucggcccag gugcaucccu 420
uaaccucagc aaggggcagc acaaucugag cacuagcuuc agcuaguuuu aggacacuag 480
ccuugcaugu aucagcaauc caacgugcua gauauccuga cauccuguga aguguaaugg 540
cauugucugc cacaggaauu gagacauuuu ggggaaaaug guuaauaacc acuguaauuu 600
ugaccccacc aaaagaaaga ucgacacuug guugugccgu cuuauguagg accaucuugg 660
ccuucuuucg guugagggaag aagacucuaa caacacccga guugaguugu ugcccuaucu 720
uaccauuaaa ugccacauac ccgaccuccg gguaaaauu agcugcauuc cguuguggua 780
caucuucaaa aaugaauugg cuugacauau uucuguagu uauaguggag cucacuacu 839

```

<210> 5
 <211> 4373
 <212> RNA
 <213> Schmallenberg virus

<400> 5
 aguaguguuu uaccacaua aaaacuucuc agcugaauaa uuacauauau auguguaacc 60
 acauauauau guuguuuuu guuuauuuu uauuguuuuu auuuauuau uuauauuugc 120
 ucauuguuau aagguuauu acuuuuuuu auuuuccauu ugguauauu ucucuuugua 180
 uucauuuuu ccuuuuagcc guuugcacag ugguuuuuu auguauagaa acagaauuag 240
 cauauuuuu gagauuuuu uauauuuuu cagucuccaa uagaaagaua gguguccaaa 300
 uagaggcuga auuuuuuagc uauuuuuuu uuuuuuuuu cugcaagacc auguagaaca 360
 cuuuuuuaua uguugcucga ugaagauuu uucauuuuu gaauuuuuu cauuuuuuug 420
 uugauuuuuu gauuuuagc guuuuuuuu agcagaagcu gagcacacac uuacugaaac 480
 ugucucuuuu gcuagugggc aguuuuuuu auuggaauu ucgcucugca ucggauugac 540
 ugcuuuuuu uuaauuuuu uauugcaguu acuuuuuuu gaacaacucc cgaugguuuu 600
 gguacuuuuu uugagugcgc aagccuuuu uucagggcag ccuuuuuuu caccacaccu 660
 gaucuuuuu auugugacug uugcuuuuu ugaauuugc uuuguuuuu auuuuuuuu 720
 cauauuuuu uauuuuuuu uaccacgcu ugaauuuuu uuauuuuuu ccuuuuuuu 780

ggugaagca	auaguuauug	uuuuuucuu	uuuccaagaga	agacaagacu	gauaugaguu	840
aucaaaagcau	cuucgaagga	ugacauuuu	acgauugaa	gcauggcaaa	cauaaucaaa	900
uuuugggguu	cccgauccaa	ugaucuuu	agaauuaau	uggacugagc	cacauuuuu	960
ugcugucgaa	ccuaagucan	ugauaucucc	aacauaaacu	uucccauuu	ugacugcaau	1020
uuuuuuuggc	auagagucca	uuugaauugu	uuggauauu	aauguauucc	ugucgcuau	1080
uaaagguugg	agaacaucaa	cgguacugca	gaaugauuca	ugggccaugg	uuauacaaac	1140
uucaaacucc	uuuuuuucaa	uacuagacuu	cuuguauauc	uuauauucag	gccuuuuuu	1200
gucugacau	gacccauua	aacaaccuuc	uuuuuuugcc	aagcaacccc	auucuuuaca	1260
gccccauua	cuugauuuu	ccuuugagaa	ugugacccaa	ccauuuugau	gugguuuuug	1320
gcuuggggc	uucccgguac	auaccuuc	gugcuuggca	uuuuuuccaa	uuuggggucc	1380
uguuuacau	agaaaucgau	acgaugcuu	uuuuuuuacu	cuucugacau	agauuuuuu	1440
ggaaaagagg	cuuuucucca	uuggcauggc	aaauuuuau	ccugcugaua	aaccuuuuu	1500
ugcagggaug	ugcgacucga	uaauacuau	ucuaauacca	uuugauaccu	uguccccau	1560
caauguacau	guuuuuuau	gaggaaauu	ugcuggaagg	uuuuuuuau	guuuuuuau	1620
gugcauaguu	aaauuuuug	cauuuucuga	cugaagcgcu	gcuauuaguu	uuucaaauu	1680
uggaugauua	auagauuuu	guguuuuuu	auuucgaa	cuuguauucc	auacuuauu	1740
ugaacaacua	cuggaacuga	augcauaacg	caaguaccag	cauuuugcug	auaaacagua	1800
caguguuua	ucguuaguuu	ucgaauuggc	uuuagcugaa	acauaguuu	auaaagccau	1860
ugagcauuu	gcauuuugcc	auugaugacc	ccuuacauua	caugauccaa	auucuuuac	1920
guugcaugau	gguauuccag	uacuauuug	cgaauucgaa	uaagucuuu	cacuuuauu	1980
gcauuuuuu	guaguuuuu	uuuuuucug	ugguuucuu	auucuuuag	aauguguguc	2040
acugcugcag	gcuuguuugu	ggucuuuau	auguuuugau	acccuuuag	auggccauu	2100
auacauuuu	gauuuugcag	auuuuuuau	uccuuggugu	gugacaccac	guggugagua	2160
gcauaccacu	uuuuuuggu	auuuugcua	caguauuggu	guuggaccug	gacuuuuu	2220
auccaaguuu	cugugggcuc	uuuuuuucaa	agauuuuau	guuuuuguu	gaggguuuu	2280
uuuuuuugc	acguuugcac	caaggauaaa	aucaacaaau	uccagaaau	uuuuuaguu	2340
uaauuuugac	ugcgauuuu	gagaaagcu	accuuuugau	uggcguaaag	cuugguaguc	2400
uuuuuuuugu	uuuuuuuug	caagcaagac	ucgaccuuu	ccagggaacua	uuuuuucuu	2460
uuuuuuucaa	uuuuuuuuc	ugcauugcuc	aaagcgauu	ggaugaccuu	uuuuuuuuu	2520
ugacauuuu	cuagcguggu	cugucuuugu	ugauugcac	uuuuuugau	acuccaagca	2580
uuuuuuuau	uuuuuuuag	uuuuuugau	gcacacuccu	aaggugaaac	uuuggggccag	2640

```

ugcuuuccau uguauguuaac uugcugaauu gauagugaaa auaucaugca cuuggagagg 2700
gcacaacuggu gauuuuauau acucauaaia aacuuagaguc ucaauaacac uagauucgga 2760
aauaaaccua ucuaugacau uacaguucac guuuaaaauu uuuaauauu cuuguucuguc 2820
uacugaagca ucugaauua uuucauugau uacaacuggu gagcuuguuu uauuuugaa 2880
aaaugccaug cacuuacuca ggugcucua uguaagcuga guugauugaa uguuuuugca 2940
guuaauacua guuuucugcg ucauuacaau uguugggacu aacagaagca uaaagauuau 3000
caaccggguc cuauuaaiaa uugauuacaa uuugaacaga cauuucucag aggcucugug 3060
aaugguuaag ccuuguuuuu cugcgcauac acaacuuaag cacuuguuug uaaaguuguc 3120
cauuauucuu aauccacguc guucaugua cauaccacaa agcugcagu ugcaguacaa 3180
gauauacuuu gcuugccuuu aaagaaauu uaacacaaau augcaugua aggaauauu 3240
aaagcuauau gugucauaa uugucaagcu uuugauaua gcuagcucuc uuuuacaugu 3300
aauauacucg ucuggcaguu uuucuaauu gauacauuga cucgauauag gugugauaaa 3360
ugagaaaaa aucagugaug uuauacacac uagcacuaa uuggauauu uacuuuuaca 3420
caauuuccuu guuuucggca augcuuuua gccagaacaa uuguuacaca ugcgaugcaa 3480
uuugagugau ucagugguag uguaaaauu uccacagauu caugcgaug ggcaauuuu 3540
aaagggaugu acugcuacaa ggcaauuuu acaaaauua aaauuuuug uguacauua 3600
agcauaaua uuacaaaag gauaaaauu aggaauaag acauaauac uauauguuu 3660
cgucaauuac aucaucauga cagacccac uaaauugaaa guuacuagca guauuaauu 3720
aagauucgua caaaaugauu cgaucauaa uucgggacag auugauccuu uaaaauagcg 3780
ggugcaugac uuauggguu ggaaacaugc augaaaaua aguguuuuu auccacaugu 3840
uaccucaaug gauucgcaug uguuuuccaa aggaauuca auuuuguuu uaaaccaacc 3900
ugauacaugc auugugcccg agauucggua gugguuaauu cgauaugaau ucaauuaaac 3960
uucgccagua ucuuuauca gugcuauuuc gcauucacu cugcaugau gcauuuagg 4020
gauuaaugug ccagauuuu cuauauucua uaucauaaag gaaccguggu caucauaau 4080
uggauugcaa gaaugccaa ccuucaccug auuaaaacga uaaauuuu uacagcagc 4140
caaccgaucu ccugauuuu aauguuacg auuugauuu augauagaua ugucgucuu 4200
cacacagcau ucugaaacga ccuuugaugu guuaacaguu uuaaacaguu cgcgauucag 4260
gaagcaccua gacccucua ugccuuuccu aagugggagu gcaaaagcu aacaggcuua 4320
guuagauuac aagacaauu ugagaagca uuugauugug guaguuaacu acu 4373

```

<210> 6

<211> 6882

<212> RNA

<213> Schmallenberg virus

<400> 6

aguagugugc	cccuauuac	augaaacuac	uuuagaauua	uuuauauaa	acagauuugg	60
ggcaaaagau	auguaauuu	uaagaucaag	cuacuggaaa	ucaaacuug	aucugccacc	120
cauuuuuuu	ccuuuuuaga	auuugugau	gocugugau	uucugcuuc	ucuccuuc	180
caucuuuuug	uaagcauacu	cuauagcuu	aguuaaggaa	ugauucagua	uagacacca	240
uggcucaaaa	uuguauucuc	ugucucgcag	uauuuuuaag	aacauaaaua	cuucauccca	300
cuuuacauu	aaugagauug	gauugucgac	aaauuuuucu	ggaacuugaa	aaugugaua	360
gauaugaucc	aucucauugc	gauauaaaca	cauguguaug	caugcuaca	guucuguaga	420
ccacugauuu	guugcgagca	uaauuaaaa	ccauguaag	uuuucuaaca	ccucagauu	480
gcuaucagau	gugaauccau	cgucuguuu	guccauuaa	ucuucaaua	uaucaauuc	540
ucuuaucaau	gcucuaacua	uaacauuuu	gaaacuauug	gauuugguug	auuucuuugu	600
guuagauacc	acuaaugcag	gugagcuau	uaauucauca	auaacauuu	cauccaaagg	660
uucacagau	aagaauucaa	augcaucuc	auccacuua	gacccucggc	augaaaauu	720
gcggcacaaa	ucuaauaag	uuauucucg	uaauuuuucu	aaccucaaau	ugagaauuu	780
uugguuucuc	auaagcuuuc	caaugucaau	gccaccgcuc	uguaugggug	ggccaucaaa	840
gaacaccauc	uuacuaaag	gggcuuuccu	aaucuuugca	ugaucuaua	cugcaaucug	900
uaguuuugua	aauuuaauuc	cccaauauu	uaacauaggg	auuuuugcaa	gacuaggcuu	960
uccaucagau	gauuuguuuu	auauagcaau	agggcaaacu	gguauccauu	uauuagucuu	1020
acguauccga	gaugcuuua	uccuugaguu	augcucucuc	auauaagau	uacuaaagac	1080
cccauaguga	uacogcuuuu	ucucacgcaa	uugguaugca	auauaccua	auuuaggauu	1140
uagaucaguc	acugguucca	uuuucucua	uuuuagccca	ugagguuugu	ucaauaaagc	1200
cuguccaugc	cuugauacua	uaucaucucu	cacucucgac	aaugcauuu	cugcagcugu	1260
aagcuugug	uccucacua	cgauccuuu	ugaccgucua	uaaccuuuga	uugauagau	1320
aaugggacca	guaguaaaug	cucgagauu	uugccaguua	uuccauguga	ucugcucuc	1380
ugcuuuuucu	gcaucaaauc	ugucaacguc	uauuugugc	aaaucgccc	ggugauauaa	1440
uaaugguua	auuuuugaac	guagucucga	auuuuugauu	uucuuuga	gacuggauac	1500
uugaacaucc	uuguauguau	auguguaau	aaugcauuu	auauaagcuu	uuuuggaguc	1560
aucuuuag	aacauaucag	caaaugugc	aaauagccug	aaacauucgu	aggcuauuug	1620
uauuuccaga	ucuaugagug	uggcuauuug	ugccuucuuu	gcugggacag	uuauuuuuu	1680
uaauaguga	acaaccaucc	auuuguguc	ugauaucaga	uuaccugua	cuaaugagca	1740
gaaaucaug	ggaguguaag	ccuuuuuug	aaggauaau	auuuuaauu	ugugucucgu	1800
ugauuucaca	uauucauaac	agaucugaua	gaauuuguc	aauccugca	cuucaauuu	1860

caaaucucgc	uucauuaacu	uaauuucauu	auuugcaauu	cucccuugca	uauuuguccu	1920
caauuuuguc	uucucuuaa	auucuuuaa	augauauua	ucucucogca	uuuacucug	1980
cuccaucccu	uuuugcucu	aguuaucugu	uacauaagca	cguaaucga	gagcaggacu	2040
augauaaaau	acuuuaaggc	ucuuaaucuc	cggcauauaa	cagcauguca	uacccaaucg	2100
uugcaucucc	acucccugua	uuuaaaauaa	caaguuguuu	gcacaagcaa	cuaauauagg	2160
gucguucauu	auacagaagc	uaauauaucg	cuuuauaucc	ucuaacauaa	guguaaaauu	2220
uuuacauca	auuuuuuuu	gcugauaugu	uucaacaaaa	gucuuuugc	caauaaucac	2280
uguagcauca	uuuauuuug	ggucaucucg	uaauccaaac	aaccuaucau	gaauacuugu	2340
auagucuauc	auugguuuau	uugcaaacaa	uacuuugucu	augaagagcu	gagcuggguu	2400
uugaauagac	aaugauucuu	uaaaauuacg	acuguuguaa	cugaacaua	cagacauaca	2460
gaacucucua	caagucucac	cuuuuguaac	caauagugua	ggguuggcua	uaaaauauuc	2520
aaauaaucuc	ucaauuuuu	guugguucug	uaauuuuuu	ugauaaucag	cauauagaug	2580
caauucagau	aacgaacucg	caguagugaa	uuuuuuggu	gucagaagag	accuagauuc	2640
cauuucacua	guuuugccca	uuccaucauc	agaugacaua	guugagucua	acgucaugua	2700
ucuuaaaagc	uuuagucuga	aaauaucaca	uugugucagu	uuacuuauu	cccauguaug	2760
uaauuuucua	uaauugaucu	ggauugguuc	acggcaaaaga	uguauagggg	acauucuuuu	2820
ugauaaaccua	acuaaaauac	uuagauuau	ugcuuuccaa	ccugcuauag	cuauaguggg	2880
uaauucugaa	uuuauuaagc	cacacaauuc	uaauaggcagc	ucaaaucuaa	caugacuagg	2940
uaaagaugaa	guaggaucau	ugauuugacc	uggaagcaug	uuauaugugc	uauguguuau	3000
ccacugaguu	aaugcaauag	caguccaucg	aagugaugga	ggugcuccau	gcuuaauugc	3060
ugucugcguu	gcagacaaac	uacuggcac	auccucuaau	gguccaaagaa	aagcacaauc	3120
gccaacagau	gucaaaauaa	agcgaccuaa	aacagaaaaa	ggcucacccau	aaauuuuaaa	3180
aauguaaacg	aacuccuuua	ugaaaauuug	uaauauaugc	uucuucauau	uugcuugauu	3240
uccaaaaguu	agacauuuuu	uuucaaauag	uuuugcagaa	aaucacauaa	caauaucauc	3300
aucuaauuuu	ucuuuggauc	ucacuaauua	agugugauug	ucaucagaa	gaaccuaga	3360
auugacuaaa	acuucccuuu	cuaguaaagu	ggcugcucuc	uuuagaauau	ccuuuaaaac	3420
auuacauaga	caugaauua	gguaagcuac	uguguaauug	agauuccccu	gcagccaguu	3480
ccguuuauua	uugaccacaa	uuugcgauaa	gccauugguc	auuucacuaa	uuauaucauc	3540
cucauguuug	auacguuggu	caaggauugc	acagagcauu	ucaucaggca	gaauuagcuu	3600
uuuuugcaua	uaauugcaua	ggaagucacaa	uaucuuuuu	uuuuuugca	gauaaagugc	3660
gggaucuaau	gcaaacacac	agaaauuuuu	gaauaaaaa	ucuuugggcac	uccauuuuga	3720

caugucugca	uugauuucac	ucuuuacaga	augugguuuu	uauugcgauca	uauuggcuuuc	3780
uucucccauu	ucugcuuauu	agcguuucuu	gaucuguuuc	auaguugcug	cugugaaucg	3840
uuuuucagac	ucugcaagcu	cuucuaauuu	uuucaauuuu	gaauccgucg	guucacuaau	3900
caucucucuc	ggauucaacu	uacagcguc	uuuagauauc	cucuccacua	aaucacagca	3960
cauuuuugcc	ucaaauucgc	cuacgaaauu	uucccuaucc	uuugcuguuu	uuuggcuuu	4020
guuaaagaau	guaaacuuaa	aaucugugug	auucuucaua	gcagagagua	uaugauacac	4080
aguggguuu	ucaucuaucu	ccuuccuuuu	uuuuuucugg	uacagagaa	caauuacuu	4140
aguggacua	augucaauu	aaucggggu	ugcuuuuuu	aagucuucau	agcgugaau	4200
ucuuauaguu	gcauuuagua	acucuucauc	aacaaauucu	ggguuugcaa	uuuauuacuu	4260
cuuuauucuc	uuugacaugc	aaucugcagc	cuuuuuuguu	gcugagcuuu	uuucuuucuc	4320
aaagucgcu	acuuuaauac	augauuuaga	gcugguuag	guagaauuag	ugcauaucca	4380
ucuuuuuag	uuguuuguu	uuucuaucgc	ugauucaaua	uaauuauugc	uagcaguguc	4440
cauuuuuaga	uuuuuugcaa	cugcauagau	aguuaauuuu	aaauuugcag	uuuuguuuuc	4500
agguguuuga	gaccuuauuc	cugggauuuu	uaucucuggg	ucccuuuuca	uaucauagau	4560
ugucuuagcc	agauucauca	uaacauaug	cuuuucaugc	aaacuuuug	aaugaagua	4620
aaugguaga	uaauuuuggu	uaauauauuc	uuuuagugau	acauagccuu	caaaccagau	4680
ugaugauagg	ucucuguuau	cucucacacc	uuuuugaguu	auuucauauu	cuguuaggca	4740
gauauuccuc	augucuaucu	uauucuuug	auuauugcc	auauaauuc	cccuuuuauu	4800
caaguuugcc	auuauuacag	agaagcuggu	cuuuugauaa	gggccaauu	uuucugcuau	4860
auaaucucua	acauagcug	auauggcuaa	ugaauucauu	aucauauauc	uugaugguuc	4920
ugucaauagc	agcauagcuu	ugguuuuaga	cagggaagug	uggaauuuaa	aaaucaugac	4980
aucagucaaa	uugagugucg	gauugucucc	ugcaaacuuc	aauguaugca	acauaaaaag	5040
ucccgguaga	cuuacuaugc	guugacauug	uuuuuuuuc	aaacgcuuuc	cuuuagagau	5100
acuaaggguu	uuugaaccag	uuuuuuuug	cgcaugcaau	gcaccguggu	gcacacauu	5160
cugaggaaga	gaauugcaac	cagcuuagaa	guuacacagu	guggaucgu	uugcuuuauu	5220
aucagaagaa	ggcauuucaa	accuuaacag	auuauuguuu	gcacacacac	cuacacgaaa	5280
aguauuuguc	cuuuuuuuu	gagaaacugc	caacuuuuu	uucaucaaga	cugaaaaauc	5340
uuuauuacaa	gcccaguuau	uugacuuucc	uauucgguuu	aucugauucc	auguauccuu	5400
ugaacauag	gcauuuuug	caccuuuuu	uucauuuua	cauccuauuc	gcucuaaguu	5460
auuauucgc	gauuauuuu	ucuuuacuuu	uucauucgg	aaauugcaaa	aaucuaugac	5520
uuccuuuuu	uugaaauuca	auuauuag	uuugucagua	uccaaauucg	cauugguuu	5580
uuuugaaaa	ugcagcugac	cccuuugcc	aagaaaauc	uuuagcauu	gugauuuguc	5640

```

uuuuguauuc auuauuucag uauccaguuu aaacugcugu ucccaauaaa uugucgccgu 5700
gccuauuuug auugguucca guuuaguauc aaucuuuuu gaugucuguc uugccauacu 5760
uuuuaguug cuagugugug cuucauauaa agcuguguc ucagaaaagu ccuaaagcau 5820
acccaaugcu cugaaugcgc uuauauaugu agacucgcc gaaauuuuu ggagugcuuu 5880
ugcaaucuug auuaguuuug gugugucgc auuugauguu ucgucagguu gacccauau 5940
gaaaugaaua gauguuuuu gcuugcugac aucuugaguc agguuucucu caguacucac 6000
ucuugaacc auuugauucc aaccgauugu gauucauca ugauuuguu uugguaguuu 6060
cccuucacau cuaaagauuc cugcagcggc cucuuucaca aaaauguuau aaucuuugcc 6120
auaucuauuu auaaccuuu guagauuuug auuccauuu ucacogcag uugcaucaa 6180
ugucauagac ucauggaug ucaguuuagc caucucaucu aaagaaucau agaauuccaa 6240
aaagacaggg ugugaauaga gcuccggggg aucucauca auccaggguc cagucaucgu 6300
aaauuacccu ugaauacaaa uuucagggaa ucuguoguca uccuuauuu ucucuuuuu 6360
cagggaucgc aaauuaaaga accaaguuuu aucaaggguu auguugagcg gcccaauuu 6420
uuccaagaau ugaauugaau uaacauggau agauucucgc agaggguagc cagggaugau 6480
cacaauuca aaaucaaaa gcaauucuga caaugcguu ccaaagauuc gggguuacuu 6540
uucauaaguu uuugacocau augcaugau aguuuaguu uuauagucuu ugaauuaaag 6600
cuugccauug ugaaugaau aaauugucgg uguacaauug cgaauuuga aagcagugcc 6660
agcuggcaga aaaucaagaa guaugucgua agcuggaaca uccugccgga auucgauauc 6720
cagguauaaa cauaccucuc uaccaagaa gucaugucua gccaugagaa gaucagcaac 6780
aaugucuuug gcuucucag cacuucgaca cugguugauc cuaucucua aaauguuuuu 6840
cuugauguc uccauaguga uuuaauuag gguuacacua cu 6882

```

<210> 7

<211> 839

<212> DNA

<213> Schmallenberg virus

<400> 7

```

agtagtgaac tccactatta actacagaaa tatgtcaagc caattcattt ttgaagatgt 60
accacaacgg aatgcagcta catttaaccc ggaggtcggg tatgtggcat ttattggtaa 120
gtatgggcaa caactcaact tcggtgttgc tagagtcttc ttctcaacc agaagaaggc 180
caagatggtc ctacataaga cggcacaacc aagtgtcgat ttacttttg gtgggtcaa 240
atttacagt gtttaataacc attttcccca atatgtctca aatcctgtgc cagacaatgc 300
cattacactt cacaggatgt caggatatct agcacgttgg attgtgata catgcaaggc 360
tagtgcctc aaactagctg aagctagtgc tcagattgtc atgcccttg ctgaggttaa 420

ggggtgcacc tgggocgatg gttatacaat gtatcttga tttgcacctg gggccgaaat 480
gttccttgat gcttttgact tctatccact agttattgaa atgcataggg tcctcaagga 540
caatatggat gtaaatttta tgaaaaaagt cctccgccaa cgctatggaa caatgactgc 600
tgaagaatgg atgactcaga aaataacaga aataaaagct gcttttaatt ctgttgga 660
gcttgcttgg gccaaatctg gattctctcc tgctgctaga accttcttgc agcaattcgg 720
tatoaacato taaactotct catcacagat ctcaatttc ogtgcaatat gtctatgtat 780
tgcacaccat tatactgcaa ggcttctgtt aagatagtta ataagtgag aacactact 839

```

<210> 8

<211> 839

<212> RNA

<213> Schmallenberg virus

<400> 8

```

aguaguguuu uccacuuuuu aacuaucuuu acagaagccu ugcaguaaa uggugugcaa      60
uacauagaca uauugcacgg aaauugaaga ucugugauga agagguuuag auguugauac      120
cgaauugcug caagaagguu cuagcagcag gagagaaucc agauuuggcc caggcaagcu      180
guccaacaga auuaaaagca gcuuuuuuuu cuuuuuuuu cuagagucac cauucuuacg      240
cagucuuugu uccauagcgu uggcggagga cuuuuuuuu aaaaauuaca uccauuuugu      300
ccuugaggac ccuauugcau ucaauaacua guggauagaa gucaaaagca ucaagggaaca      360
uuuogggccc aggugcaaa ccaagauaca uuguuaaacc aucggcccag gugcaucccu      420
uaaccucacg aaggggcaug acaaucugag cacuagcuuc agcuaguug aggacacua      480
ccuugcaugu aucagcaau caacgugcua gauaucuga cauccuguga aguguaaugg      540
cauugucugg cacaggauuu gagacauuu ggggaaaau gguuuuaacc acuguaauu      600
ugaccccacc aaaaguaaga ucgacacuug guugugccgu cuuauuguagg accaucuugg      660
ccuucuuug guugaggaag aagacucua caacaccgaa guugaguugu ugcccuaucu      720
uaccaaaaa ugccacauac ccgaccuccg gguuaaaugu agcugcauuc cguuguggua      780
caucuucaaa aaugaauugg cuugacauau uucuguagu uauaguggag uucacuacu      839

```

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **K. TAMURAMEGA5:** Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods *Mol. Biol. Evol.*, 2011, vol. 28, 2731-2739 [\[0026\]](#)
- **B. HOFFMANN .M. SCHEUCHD. HÖPERR. JUNGBLUTM. HOLSTEGH. SCHIRRMIEERM. ESCHBAUMERK. V. GOLLERK. WERNIKEM. FISCHER** Novel orthobunyavirus in Cattle, Europe *Emerg. Infect. Dis.*, 2011, vol. 18, 469-472 [\[0137\]](#)
- **M.-M. GARIGLINANY et al.** Schmallenberg virus in calf born at term with porencephaly, Belgium *Emerg. Infect. Dis.*, 2012, vol. 18, [\[0137\]](#)
- **M. D. BOWEN et al.** A reassortant bunyavirus isolated from acute hemorrhagic fever cases in Kenya and Somalia *Virology*, 2001, vol. 291, 185-190 [\[0137\]](#)
- **Virus Taxonomy:** Ninth Report of the International Committee on Taxonomy of Viruses *Elsevier* 2011 0000725-731 [\[0137\]](#)
- **R. M. KINNEYC. H. CALISHER** Antigenic relationships among Simbu serogroup (Bunyaviridae) viruses *Am. J. Trop. Med. Hyg.*, 1981, vol. 30, 1307-1318 [\[0137\]](#)
- **M. F. SAEEDL. LIH. WANGS. C. WEAVERA. D. BARRETT** Phylogeny of the Simbu serogroup of the genus Bunyavirus *J. Gen. Virol.*, 2001, vol. 82, 2173-2181 [\[0137\]](#)
- **BILK SSCHULZE CFISCHER MBEER MHLINAK AHOFFMANN B.** Organ distribution of Schmallenberg virus RNA in malformed newborns *Veterinary microbiology*, 2012, [\[0137\]](#)
- **KORTEKAAS JANTONIS AFKANT JVLOET RPVOGEL AORESHKOVA N et al.** Efficacy of three candidate Rift Valley fever vaccines in sheep *Vaccine*, 2012, vol. 30, 2334-2339 [\[0137\]](#)
- **KUROGI HINABA YTAHASHI ESATO KGOTO YSATODA K et al.** Development of inactivated vaccine for Akabane disease *National Institute of Animal Health quarterly* 1978 Winter, vol. 18, 3-497-108 [\[0137\]](#)
- **KUROGI HINABA YAKASHI HTAKAHASHI ESATO KSATODA K et al.** Immune response of various animals to Akabane disease live virus vaccine *National Institute of Animal Health quarterly* 1979 Summer, vol. 19, 1-223-31 [\[0137\]](#)

P A T E N T K R A V

1. Immunogen sammensætning omfattende inaktiveret Schmallerbergvirus (SBV).
2. Immunogen sammensætning ifølge krav 1, hvor SBV'et omfatter:
 - (a) et lille (S) RNA-segment, der har en sekvens, som er invers komplementær til en nukleinsyresekvens, der har mindst 97,8 % sekvensidentitet med nukleinsyresekvensen ifølge SEQ ID NO:1 eller SEQ ID NO:7;
 - (b) et medium (M) RNA-segment, der har en sekvens, som er invers komplementær til en nukleinsyresekvens, der har mindst 82,2 % sekvensidentitet med nukleinsyresekvensen ifølge SEQ ID NO:2;
 - 10 - (c) et stort (L) RNA-segment, der har en sekvens, som er invers komplementær til en nukleinsyresekvens, der har mindst 93 % sekvensidentitet med nukleinsyresekvensen ifølge SEQ ID NO:3; eller
 - (d) kombinationer deraf.
3. Immunogen sammensætning ifølge krav 1, hvor SBV'et omfatter:
 - 15 - (a) et S-RNA-segment, k e n d e t e g n e t ved, at S-RNA-segmentet har en sekvens, der har mindst 97,8 % sekvensidentitet med SEQ ID NO:4 eller SEQ ID NO:8;
 - (b) et M-RNA-segment, k e n d e t e g n e t ved, at M-RNA-segmentet har en sekvens, der har mindst 82,2 % sekvensidentitet med SEQ ID NO:5;
 - (c) et L-RNA-segment, k e n d e t e g n e t ved, at L-RNA-segmentet har en sekvens,
 - 20 der har mindst 93 % sekvensidentitet med SEQ ID NO:6; eller
 - (d) kombinationer deraf.
4. Immunogen sammensætning ifølge krav 1, hvor SBV er inaktiveret ved varmebehandling eller med et virusinaktiveringsmiddel.
5. Immunogen sammensætning ifølge krav 4, hvor virusinaktiveringsmidlet er en aziridinforbindelse.
- 25 6. Immunogen sammensætning ifølge krav 5, hvor aziridinforbindelsen er binært ethylenimin (BEI).
7. Immunogen sammensætning ifølge krav 1, omfattende en mængde af SBV, som er ækvivalent med en virustiter på mindst omkring 10^5 TCID₅₀/mL per dosis, eller, hvor SBV'et
- 30 har en titer før inaktivering på mindst omkring 10^6 SBV-partikler per milliliter.
8. Immunogen sammensætning ifølge krav 1, yderligere indeholdende ét eller flere farmaceutisk acceptable bærestoffer eller excipienser,
 - eller yderligere omfattende aluminiumhydroxid, saponin eller kombinationer deraf.
9. Immunogen sammensætning ifølge krav 8,
- 35 hvor det ene eller flere farmaceutisk acceptable bærestoffer eller excipienser er valgt fra gruppen bestående af solventer, dispersionsmedier, adjuvanter, stabiliseringsmidler, fortyndingsmidler, konserveringsmidler, antibakterielle midler og antimykotika, isotoniske midler og adsorptionsforsinkende middel.
10. Immunogen sammensætning ifølge krav 1 til anvendelse som et lægemiddel.

11. Immunogen sammensætning ifølge krav 1 til anvendelse som en vaccine.

12. Immunogen sammensætning ifølge krav 1 til anvendelse i en fremgangsmåde til frembringelse af et immunrespons mod SBV i et dyr, hvor den immunogene sammensætning er til indgivelse til dyret.

5 13. Immunogen sammensætning ifølge krav 1 til anvendelse i en fremgangsmåde til
- at behandle eller at forebygge SBV i et dyr eller
- at behandle eller at forebygge viræmi eller misdannelser induceret af SBV,
hvor en terapeutisk virkningsfuld mængde af den immunogene sammensætning er til
indgivelse til dyret.

10 14. Immunogen sammensætning ifølge krav 1 til anvendelse i en fremgangsmåde til
- at inducere et immunrespons mod SBV i en besætning af dyr eller
- at forebygge eller at reducere viræmi eller misdannelser induceret af SBV i en be-
sætning af dyr eller
- at forebygge eller at reducere smitteoverførslen af SBV i en besætning af dyr,
15 hvor den immunogene sammensætning er til indgivelse til sådanne dyr med behov
derfor.

15. Immunogen sammensætning til anvendelse ifølge krav 13 eller 14, hvor den im-
munogene sammensætning er til indgivelse i en enkelt dose eller i to doser.